{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T15:02:38Z","timestamp":1789398158941,"version":"build-2803163510"},"reference-count":208,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,28]],"date-time":"2026-06-28T00:00:00Z","timestamp":1782604800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T00:00:00Z","timestamp":1789344000000},"content-version":"vor","delay-in-days":78,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100005047","name":"Natural Science Foundation of Liaoning Province","doi-asserted-by":"publisher","award":["2024-MSLH-263"],"award-info":[{"award-number":["2024-MSLH-263"]}],"id":[{"id":"10.13039\/501100005047","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Nanobiotechnol"],"DOI":"10.1186\/s12951-026-04724-4","type":"journal-article","created":{"date-parts":[[2026,6,28]],"date-time":"2026-06-28T04:35:34Z","timestamp":1782621334000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Engineering smart polymeric lipid nanoparticles for breast cancer: AI-guided formulation design, biological barriers, and translational constraints"],"prefix":"10.1186","volume":"24","author":[{"given":"Tianzhao","family":"Du","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ye","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruihan","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cui","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhichao","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,28]]},"reference":[{"key":"4724_CR1","doi-asserted-by":"publisher","first-page":"117009","DOI":"10.1016\/j.lfs.2019.117009","volume":"239","author":"I Janu\u0161kevi\u010dien\u0117","year":"2019","unstructured":"Janu\u0161kevi\u010dien\u0117 I, Petrikait\u0117 V. Heterogeneity of breast cancer: The importance of interaction between different tumor cell populations. Life Sci. 2019;239:117009.","journal-title":"Life Sci"},{"issue":"1","key":"4724_CR2","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s40164-022-00363-1","volume":"12","author":"L Guo","year":"2023","unstructured":"Guo L, Kong D, Liu J, Zhan L, Luo L, Zheng W, et al. Breast cancer heterogeneity and its implication in personalized precision therapy. Exp Hematol Oncol. 2023;12(1):3.","journal-title":"Exp Hematol Oncol"},{"issue":"23","key":"4724_CR3","doi-asserted-by":"publisher","first-page":"11599","DOI":"10.3390\/ijms262311599","volume":"26","author":"A Kotsifaki","year":"2025","unstructured":"Kotsifaki A, Kalouda G, Karalexis E, Stathaki M, Metaxas G, Armakolas A. Emerging Breast Cancer Subpopulations: Functional Heterogeneity Beyond the Classical Subtypes. Int J Mol Sci [Internet]. 2025;26(23):11599.","journal-title":"Int J Mol Sci [Internet]"},{"issue":"23","key":"4724_CR4","doi-asserted-by":"publisher","first-page":"14937","DOI":"10.3390\/ijms232314937","volume":"23","author":"E Kudelova","year":"2022","unstructured":"Kudelova E, Smolar M, Holubekova V, Hornakova A, Dvorska D, Lucansky V, et al. Genetic Heterogeneity, Tumor Microenvironment and Immunotherapy in Triple-Negative Breast Cancer. Int J Mol Sci [Internet]. 2022;23(23):14937.","journal-title":"Int J Mol Sci [Internet]"},{"key":"4724_CR5","doi-asserted-by":"publisher","first-page":"217865","DOI":"10.1016\/j.canlet.2025.217865","volume":"628","author":"H Sabit","year":"2025","unstructured":"Sabit H, Adel A, Abdelfattah MM, Ramadan RM, Nazih M, Abdel-Ghany S, et al. The role of tumor microenvironment and immune cell crosstalk in triple-negative breast cancer (TNBC): Emerging therapeutic opportunities. Cancer Lett. 2025;628:217865.","journal-title":"Cancer Lett"},{"issue":"2","key":"4724_CR6","first-page":"167","volume":"2","author":"C Paus","year":"2021","unstructured":"Paus C, van der Voort R, Cambi A. Nanomedicine in cancer therapy: promises and hurdles of polymeric nanoparticles. Explor Med. 2021;2(2):167\u201385.","journal-title":"Explor Med"},{"issue":"10","key":"4724_CR7","doi-asserted-by":"publisher","first-page":"12281","DOI":"10.1021\/acsnano.9b09713","volume":"14","author":"D Sun","year":"2020","unstructured":"Sun D, Zhou S, Gao W. What Went Wrong with Anticancer Nanomedicine Design and How to Make It Right. ACS Nano. 2020;14(10):12281\u201390.","journal-title":"ACS Nano"},{"issue":"12","key":"4724_CR8","doi-asserted-by":"publisher","first-page":"10082","DOI":"10.3390\/ijms241210082","volume":"24","author":"J Kim","year":"2023","unstructured":"Kim J, Cho H, Lim D-K, Joo MK, Kim K. Perspectives for Improving the Tumor Targeting of Nanomedicine via the EPR Effect in Clinical Tumors. Int J Mol Sci [Internet]. 2023;24(12):10082.","journal-title":"Int J Mol Sci [Internet]"},{"issue":"12","key":"4724_CR9","doi-asserted-by":"publisher","first-page":"2904","DOI":"10.3390\/cancers14122904","volume":"14","author":"MU Munir","year":"2022","unstructured":"Munir MU. Nanomedicine penetration to tumor: challenges, and advanced strategies to tackle this issue. Cancers (Basel). 2022;14(12):2904. https:\/\/doi.org\/10.3390\/cancers14122904","journal-title":"Cancers (Basel)"},{"issue":"9","key":"4724_CR10","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1038\/s41565-018-0246-4","volume":"13","author":"M Faria","year":"2018","unstructured":"Faria M, Bj\u00f6rnmalm M, Thurecht KJ, Kent SJ, Parton RG, Kavallaris M, et al. Minimum information reporting in bio-nano experimental literature. Nat Nanotechnol. 2018;13(9):777\u201385.","journal-title":"Nat Nanotechnol"},{"issue":"8","key":"4724_CR11","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.3390\/pharmaceutics13081291","volume":"13","author":"D Sivadasan","year":"2021","unstructured":"Sivadasan D, Sultan MH, Madkhali O, Almoshari Y, Thangavel N. Polymeric lipid hybrid nanoparticles (PLNs) as emerging drug delivery platform-a comprehensive review of their properties, preparation methods, and therapeutic applications. Pharmaceutics. 2021;13(8):1291. https:\/\/doi.org\/10.3390\/pharmaceutics13081291.","journal-title":"Pharmaceutics."},{"issue":"9","key":"4724_CR12","doi-asserted-by":"publisher","first-page":"2247","DOI":"10.1021\/acs.bioconjchem.9b00448","volume":"30","author":"Y Huai","year":"2019","unstructured":"Huai Y, Hossen MN, Wilhelm S, Bhattacharya R, Mukherjee P. Nanoparticle Interactions with the Tumor Microenvironment. Bioconjug Chem. 2019;30(9):2247\u201363.","journal-title":"Bioconjug Chem"},{"issue":"1","key":"4724_CR13","doi-asserted-by":"publisher","first-page":"8294","DOI":"10.1038\/s41598-020-65162-2","volume":"10","author":"IM Chamseddine","year":"2020","unstructured":"Chamseddine IM, Frieboes HB, Kokkolaras M. Multi-objective optimization of tumor response to drug release from vasculature-bound nanoparticles. Sci Rep. 2020;10(1):8294.","journal-title":"Sci Rep"},{"issue":"1","key":"4724_CR14","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1186\/s12951-025-03947-1","volume":"24","author":"L Zhao","year":"2025","unstructured":"Zhao L, Liu X, Deng X. AI-engineered multifunctional nanoplatforms: synergistically bridging precision diagnosis and intelligent therapy in next-generation oncology. J Nanobiotechnology. 2025;24(1):73. https:\/\/doi.org\/10.1186\/s12951-025-03947-1","journal-title":"J Nanobiotechnology"},{"issue":"22","key":"4724_CR15","doi-asserted-by":"publisher","first-page":"11121","DOI":"10.3390\/ijms262211121","volume":"26","author":"Y Han","year":"2025","unstructured":"Han Y, Kim DH, Pack SP. Nanomaterials in Drug Delivery: Leveraging Artificial Intelligence and Big Data for Predictive Design. Int J Mol Sci. 2025;26(22):11121.","journal-title":"Int J Mol Sci"},{"issue":"2","key":"4724_CR16","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1007\/s13346-021-00929-2","volume":"11","author":"E Egorov","year":"2021","unstructured":"Egorov E, Pieters C, Korach-Rechtman H, Shklover J, Schroeder A. Robotics, microfluidics, nanotechnology and AI in the synthesis and evaluation of liposomes and polymeric drug delivery systems. Drug Deliv Transl Res. 2021;11(2):345\u201352.","journal-title":"Drug Deliv Transl Res"},{"issue":"14","key":"4724_CR17","doi-asserted-by":"publisher","first-page":"1775","DOI":"10.1080\/17435889.2025.2523730","volume":"20","author":"M Alawi","year":"2025","unstructured":"Alawi M, Hilles AR, Kumar M, Ansari MD, Mahmood S. Lipid-polymer hybrid nanoparticles: a cutting-edge frontier in breast cancer treatment strategies. Nanomed (Lond). 2025;20(14):1775\u201398.","journal-title":"Nanomed (Lond)"},{"issue":"1","key":"4724_CR18","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1186\/s12943-023-01849-0","volume":"22","author":"KR Gajbhiye","year":"2023","unstructured":"Gajbhiye KR, Salve R, Narwade M, Sheikh A, Kesharwani P, Gajbhiye V. Lipid polymer hybrid nanoparticles: a custom-tailored next-generation approach for cancer therapeutics. Mol Cancer. 2023;22(1):160.","journal-title":"Mol Cancer"},{"key":"4724_CR19","doi-asserted-by":"publisher","first-page":"105827","DOI":"10.1016\/j.jddst.2024.105827","volume":"97","author":"D Karati","year":"2024","unstructured":"Karati D, Mukherjee S, Prajapati B, Bose A, Paul S, Elossaily GM, et al. A review on lipid-polymer hybrid nanocarriers in cancer. J Drug Deliv Sci Technol. 2024;97:105827.","journal-title":"J Drug Deliv Sci Technol"},{"issue":"12","key":"4724_CR20","doi-asserted-by":"publisher","first-page":"1772","DOI":"10.3390\/ph18121772","volume":"18","author":"S Jacob","year":"2025","unstructured":"Jacob S, Varkey NR, Boddu SHS, Gorain B, Rao R, Nair AB. Advances in lipid-polymer hybrid nanoparticles: design strategies, functionalization, oncological and non-oncological clinical prospects. Pharmaceuticals (Basel). 2025;18(12):1772. https:\/\/doi.org\/10.3390\/ph18121772.","journal-title":"Pharmaceuticals (Basel)."},{"issue":"1","key":"4724_CR21","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1186\/s11671-023-03897-3","volume":"18","author":"S Salel","year":"2023","unstructured":"Salel S, Iyisan B. Polymer\u2013lipid hybrid nanoparticles as potential lipophilic anticancer drug carriers. Discover Nano. 2023;18(1):114.","journal-title":"Discover Nano"},{"key":"4724_CR22","doi-asserted-by":"publisher","first-page":"100165","DOI":"10.1016\/j.medidd.2023.100165","volume":"20","author":"S Parveen","year":"2023","unstructured":"Parveen S, Gupta P, Kumar S, Banerjee M. Lipid polymer hybrid nanoparticles as potent vehicles for drug delivery in cancer therapeutics. Med Drug Discovery. 2023;20:100165.","journal-title":"Med Drug Discovery"},{"issue":"8","key":"4724_CR23","doi-asserted-by":"publisher","first-page":"2986","DOI":"10.1016\/j.xphs.2021.04.006","volume":"110","author":"H Liu","year":"2021","unstructured":"Liu H, Zhuang Y, Wang P, Zou T, Lan M, Li L, et al. Polymeric Lipid Hybrid Nanoparticles as a Delivery System Enhance the Antitumor Effect of Emodin in Vitro and in Vivo. J Pharm Sci. 2021;110(8):2986\u201396.","journal-title":"J Pharm Sci"},{"issue":"45","key":"4724_CR24","doi-asserted-by":"publisher","first-page":"10859","DOI":"10.1039\/D3TB01317K","volume":"11","author":"KS Pradyuth","year":"2023","unstructured":"Pradyuth KS, Salunkhe SA, Singh AK, Chitkara D, Mittal A. Belinostat loaded lipid-polymer hybrid nanoparticulate delivery system for breast cancer: improved pharmacokinetics and biodistribution in a tumor model. J Mater Chem B. 2023;11(45):10859\u201372.","journal-title":"J Mater Chem B"},{"issue":"12","key":"4724_CR25","doi-asserted-by":"publisher","first-page":"2459","DOI":"10.3390\/polym14122459","volume":"14","author":"MM Ahmed","year":"2022","unstructured":"Ahmed MM, Anwer MK, Fatima F, Aldawsari MF, Alalaiwe A, Alali AS, et al. Boosting the anticancer activity of sunitinib malate in breast cancer through lipid polymer hybrid nanoparticles approach. Polymers. 2022;14(12):2459. https:\/\/doi.org\/10.3390\/polym14122459.","journal-title":"Polymers."},{"key":"4724_CR26","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1016\/j.jconrel.2022.11.009","volume":"352","author":"N Rajana","year":"2022","unstructured":"Rajana N, Mounika A, Chary PS, Bhavana V, Urati A, Khatri D, et al. Multifunctional hybrid nanoparticles in diagnosis and therapy of breast cancer. J Control Release. 2022;352:1024\u201347.","journal-title":"J Control Release"},{"issue":"6","key":"4724_CR27","doi-asserted-by":"publisher","first-page":"1771","DOI":"10.3390\/pharmaceutics15061771","volume":"15","author":"J Suksiriworapong","year":"2023","unstructured":"Suksiriworapong J, Pongprasert N, Bunsupa S, Taresco V, Crucitti VC, Janurai T, et al. CD44-targeted lipid polymer hybrid nanoparticles enhance anti-breast cancer effect of Cordyceps militaris extracts. Pharmaceutics. 2023;15(6):1771. https:\/\/doi.org\/10.3390\/pharmaceutics15061771.","journal-title":"Pharmaceutics."},{"issue":"13","key":"4724_CR28","doi-asserted-by":"publisher","first-page":"2844","DOI":"10.3390\/polym15132844","volume":"15","author":"R Al-Shdefat","year":"2023","unstructured":"Al-Shdefat R, Hailat M, Alshogran OY, Abu Dayyih W, Gardouh A, Al Meanazel O. Ribociclib hybrid lipid-polymer nanoparticle preparation and characterization for cancer treatment. Polymers. 2023;15(13):2844. https:\/\/doi.org\/10.3390\/polym15132844.","journal-title":"Polymers."},{"issue":"10","key":"4724_CR29","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1080\/03639045.2024.2421198","volume":"50","author":"H Sarma","year":"2024","unstructured":"Sarma H, Dutta A, Bharali A, Rahman SS, Baruah S, Biswas N, et al. pH sensitive lipid polymeric hybrid nanoparticle (LPHNP) of paclitaxel and curcumin for targeted delivery in breast cancer. Drug Dev Ind Pharm. 2024;50(10):856\u201364.","journal-title":"Drug Dev Ind Pharm"},{"issue":"27","key":"4724_CR30","doi-asserted-by":"publisher","first-page":"2411","DOI":"10.2217\/nnm-2021-0241","volume":"16","author":"F Liu","year":"2021","unstructured":"Liu F, Li L, Lan M, Zou T, Kong Z, Cai T, et al. Psoralen-loaded polymeric lipid nanoparticles combined with paclitaxel for the treatment of triple-negative breast cancer. Nanomed (Lond). 2021;16(27):2411\u201330.","journal-title":"Nanomed (Lond)"},{"key":"4724_CR31","doi-asserted-by":"publisher","first-page":"119565","DOI":"10.1016\/j.ijpharm.2020.119565","volume":"586","author":"F Bakar-Ates","year":"2020","unstructured":"Bakar-Ates F, Ozkan E, Sengel-Turk CT. Encapsulation of cucurbitacin B into lipid polymer hybrid nanocarriers induced apoptosis of MDAMB231 cells through PARP cleavage. Int J Pharm. 2020;586:119565.","journal-title":"Int J Pharm"},{"key":"4724_CR32","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2020.119246","volume":"580","author":"TE Yalcin","year":"2020","unstructured":"Yalcin TE, Ilbasmis-Tamer S, Takka S. Antitumor activity of gemcitabine hydrochloride loaded lipid polymer hybrid nanoparticles (LPHNs): in vitro and in vivo. Int J Pharm. 2020;580:119246.","journal-title":"Int J Pharm"},{"key":"4724_CR33","doi-asserted-by":"publisher","first-page":"4961","DOI":"10.2147\/IJN.S209325","volume":"14","author":"N Tahir","year":"2019","unstructured":"Tahir N, Madni A, Correia A, Rehman M, Balasubramanian V, Khan MM, et al. Lipid-polymer hybrid nanoparticles for controlled delivery of hydrophilic and lipophilic doxorubicin for breast cancer therapy. Int J Nanomed. 2019;14:4961\u201374.","journal-title":"Int J Nanomed"},{"key":"4724_CR34","doi-asserted-by":"publisher","first-page":"102445","DOI":"10.1016\/j.mtbio.2025.102445","volume":"35","author":"I Alradwan","year":"2025","unstructured":"Alradwan I, Zhi P, Zetrini AE, Wang L, He C, Rezaeifarimani M, et al. Empowering chemotherapy-induced antitumor immunity by multi-targeted synergistic combination nanomedicine for triple-negative breast cancer. Mater Today Bio. 2025;35:102445.","journal-title":"Mater Today Bio"},{"issue":"7","key":"4724_CR35","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.1021\/acs.bioconjchem.5c00205","volume":"36","author":"R Das","year":"2025","unstructured":"Das R, Medeiros J, Krishna J, Munugoti S, Dutta R, Devarajan A, et al. Multicheckpoint Cellular Targeting of siRNAs Using Antibody-Directed Lipid-Polymer Hybrid Nanoparticles. Bioconjug Chem. 2025;36(7):1527\u201340.","journal-title":"Bioconjug Chem"},{"issue":"6","key":"4724_CR36","doi-asserted-by":"publisher","first-page":"864","DOI":"10.3390\/ph18060864","volume":"18","author":"A Manda","year":"2025","unstructured":"Manda A, Alhazza A, Uluda\u011f H, Montazeri Aliabadi H. Engineering lipid-polymer nanoparticles for siRNA delivery to cancer cells. Pharmaceuticals (Basel). 2025;18(6):864. https:\/\/doi.org\/10.3390\/ph18060864.","journal-title":"Pharmaceuticals (Basel)."},{"key":"4724_CR37","doi-asserted-by":"publisher","first-page":"4147","DOI":"10.2147\/IJN.S134148","volume":"12","author":"F Gao","year":"2017","unstructured":"Gao F, Zhang J, Fu C, Xie X, Peng F, You J, et al. iRGD-modified lipid-polymer hybrid nanoparticles loaded with isoliquiritigenin to enhance anti-breast cancer effect and tumor-targeting ability. Int J Nanomed. 2017;12:4147\u201362.","journal-title":"Int J Nanomed"},{"issue":"Pt 4","key":"4724_CR38","doi-asserted-by":"publisher","first-page":"141754","DOI":"10.1016\/j.ijbiomac.2025.141754","volume":"306","author":"M Narwade","year":"2025","unstructured":"Narwade M, Haldar N, Samanta R, Pawar A, Gajbhiye V, Gajbhiye KR. \u03b1(v)\u03b2(3) integrin aptamer functionalized pH-responsive lipid polymer hybrid nanoparticles for targeted co-delivery of paclitaxel and tamoxifen. Int J Biol Macromol. 2025;306(Pt 4):141754.","journal-title":"Int J Biol Macromol"},{"issue":"6","key":"4724_CR39","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1007\/s12094-020-02507-3","volume":"23","author":"M Khodaei","year":"2021","unstructured":"Khodaei M, Rostamizadeh K, Taromchi AH, Monirinasab H, Fathi M. DDAB cationic lipid-mPEG, PCL copolymer hybrid nano-carrier synthesis and application for delivery of siRNA targeting IGF-1R into breast cancer cells. Clin Transl Oncol. 2021;23(6):1167\u201378.","journal-title":"Clin Transl Oncol"},{"issue":"2","key":"4724_CR40","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3390\/bioengineering13020209","volume":"13","author":"F Roffo","year":"2026","unstructured":"Roffo F, Orlandella FM, Luciano N, Salvatore G, Torino E. Lipid-polymer nanoparticles (LiPoNs) mediated codelivery of AntimiR-21 and gadolinium chelate in triple negative breast cancer theranostics. Bioengineering. 2026;13(2):209. https:\/\/doi.org\/10.3390\/bioengineering13020209.","journal-title":"Bioengineering."},{"key":"4724_CR41","doi-asserted-by":"publisher","first-page":"111760","DOI":"10.1016\/j.colsurfb.2021.111760","volume":"203","author":"RS Jadon","year":"2021","unstructured":"Jadon RS, Sharma G, Garg NK, Tandel N, Gajbhiye KR, Salve R, et al. Efficient in vitro and in vivo docetaxel delivery mediated by pH-sensitive LPHNPs for effective breast cancer therapy. Colloids Surf B Biointerfaces. 2021;203:111760.","journal-title":"Colloids Surf B Biointerfaces"},{"issue":"11","key":"4724_CR42","doi-asserted-by":"publisher","first-page":"2394","DOI":"10.3390\/pharmaceutics14112394","volume":"14","author":"RS Fernandes","year":"2022","unstructured":"Fernandes RS, Arribada RG, Silva JO, Silva-Cunha A, Townsend DM, Ferreira LAM, et al. In vitro and in vivo effect of pH-sensitive PLGA-TPGS-based hybrid nanoparticles loaded with doxorubicin for breast cancer therapy. Pharmaceutics. 2022;14(11):2394. https:\/\/doi.org\/10.3390\/pharmaceutics14112394.","journal-title":"Pharmaceutics."},{"issue":"3","key":"4724_CR43","doi-asserted-by":"publisher","first-page":"1262","DOI":"10.1016\/j.apsb.2022.11.009","volume":"13","author":"S Shen","year":"2023","unstructured":"Shen S, Li T, Fan J, Shao Q, Dong H, Xu X, et al. Lipid-polymer hybrid nanoparticle with cell-distinct drug release for treatment of stemness-derived resistant tumor. Acta Pharm Sin B. 2023;13(3):1262\u201373.","journal-title":"Acta Pharm Sin B"},{"issue":"1","key":"4724_CR44","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1186\/s12943-023-01849-0","volume":"22","author":"KR Gajbhiye","year":"2023","unstructured":"Gajbhiye KR, Salve R, Narwade M, Sheikh A, Kesharwani P, Gajbhiye V. Lipid polymer hybrid nanoparticles: a custom-tailored next-generation approach for cancer therapeutics. Mol Cancer. 2023;22(1):160.","journal-title":"Mol Cancer"},{"issue":"8","key":"4724_CR45","doi-asserted-by":"publisher","first-page":"4949","DOI":"10.1021\/acsabm.0c00488","volume":"3","author":"G Birlik Demirel","year":"2020","unstructured":"Birlik Demirel G, Aygul E, Dag A, Atasoy S, Cimen Z, Cetin B. Folic Acid-Conjugated pH and Redox-Sensitive Ellipsoidal Hybrid Magnetic Nanoparticles for Dual-Triggered Drug Release. ACS Appl Bio Mater. 2020;3(8):4949\u201361.","journal-title":"ACS Appl Bio Mater"},{"issue":"7","key":"4724_CR46","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1208\/s12249-020-01812-y","volume":"21","author":"S Sharma","year":"2020","unstructured":"Sharma S, Pukale SS, Sahel DK, Agarwal DS, Dalela M, Mohanty S, et al. Folate-Targeted Cholesterol-Grafted Lipo-Polymeric Nanoparticles for Chemotherapeutic Agent Delivery. AAPS PharmSciTech. 2020;21(7):280.","journal-title":"AAPS PharmSciTech"},{"key":"4724_CR47","first-page":"2101","volume":"10","author":"L Zhang","year":"2015","unstructured":"Zhang L, Zhu D, Dong X, Sun H, Song C, Wang C, et al. Folate-modified lipid-polymer hybrid nanoparticles for targeted paclitaxel delivery. Int J Nanomed. 2015;10:2101\u201314.","journal-title":"Int J Nanomed"},{"issue":"4","key":"4724_CR48","doi-asserted-by":"publisher","first-page":"2177","DOI":"10.3390\/ijms23042386","volume":"23","author":"M Curcio","year":"2022","unstructured":"Curcio M, Brindisi M, Cirillo G, Frattaruolo L, Leggio A, Rago V, et al. Smart lipid-polysaccharide nanoparticles for targeted delivery of doxorubicin to breast cancer cells. Int J Mol Sci. 2022;23(4):2177. https:\/\/doi.org\/10.3390\/ijms23042386.","journal-title":"Int J Mol Sci."},{"issue":"1","key":"4724_CR49","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1007\/s00210-025-04408-0","volume":"399","author":"N Dasari","year":"2026","unstructured":"Dasari N, Guntuku GS, Pindiprolu S. Lipid-chondroitin sulfate conjugate modified PLGA nanocarriers of salinomycin for enhanced TRAIL-mediated apoptosis in triple negative breast cancer. Naunyn Schmiedebergs Arch Pharmacol. 2026;399(1):349\u201367.","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"4724_CR50","doi-asserted-by":"publisher","first-page":"112008","DOI":"10.1016\/j.colsurfb.2021.112008","volume":"207","author":"H Zhang","year":"2021","unstructured":"Zhang H, Li J, Yuan R, Li Y, Zhang Y, Hu X, et al. Augment the efficacy of eradicating metastatic lesions and tumor proliferation in breast cancer by honokiol-loaded pH-sensitive targeted lipid nanoparticles. Colloids Surf B Biointerfaces. 2021;207:112008.","journal-title":"Colloids Surf B Biointerfaces"},{"issue":"1","key":"4724_CR51","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.ejpb.2012.02.005","volume":"81","author":"HY Xue","year":"2012","unstructured":"Xue HY, Wong HL. Targeting megalin to enhance delivery of anti-clusterin small-interfering RNA nanomedicine to chemo-treated breast cancer. Eur J Pharm Biopharm. 2012;81(1):24\u201332.","journal-title":"Eur J Pharm Biopharm"},{"issue":"11","key":"4724_CR52","doi-asserted-by":"publisher","first-page":"2212","DOI":"10.1016\/j.apsb.2020.07.006","volume":"10","author":"H Yang","year":"2020","unstructured":"Yang H, Le QV, Shim G, Oh YK, Shin YK. Molecular engineering of antibodies for site-specific conjugation to lipid polydopamine hybrid nanoparticles. Acta Pharm Sin B. 2020;10(11):2212\u201326.","journal-title":"Acta Pharm Sin B"},{"issue":"6","key":"4724_CR53","doi-asserted-by":"publisher","first-page":"1883","DOI":"10.1021\/acs.molpharmaceut.6b01148","volume":"14","author":"NK Garg","year":"2017","unstructured":"Garg NK, Tyagi RK, Sharma G, Jain A, Singh B, Jain S, et al. Functionalized Lipid-Polymer Hybrid Nanoparticles Mediated Codelivery of Methotrexate and Aceclofenac: A Synergistic Effect in Breast Cancer with Improved Pharmacokinetics Attributes. Mol Pharm. 2017;14(6):1883\u201397.","journal-title":"Mol Pharm"},{"issue":"15","key":"4724_CR54","doi-asserted-by":"publisher","first-page":"1851","DOI":"10.2217\/nnm-2017-0011","volume":"12","author":"A Jain","year":"2017","unstructured":"Jain A, Sharma G, Kushwah V, Garg NK, Kesharwani P, Ghoshal G, et al. Methotrexate and beta-carotene loaded-lipid polymer hybrid nanoparticles: a preclinical study for breast cancer. Nanomed (Lond). 2017;12(15):1851\u201372.","journal-title":"Nanomed (Lond)"},{"issue":"Pt 1","key":"4724_CR55","doi-asserted-by":"publisher","first-page":"128821","DOI":"10.1016\/j.ijbiomac.2023.128821","volume":"258","author":"YS Pooja","year":"2024","unstructured":"Pooja YS, Rajana N, Yadav R, Naraharisetti LT, Godugu C, Mehra NK. Design, development, and evaluation of CDK-4\/6 inhibitor loaded 4-carboxy phenyl boronic acid conjugated pH-sensitive chitosan lecithin nanoparticles in the management of breast cancer. Int J Biol Macromol. 2024;258(Pt 1):128821.","journal-title":"Int J Biol Macromol"},{"issue":"23","key":"4724_CR56","doi-asserted-by":"publisher","first-page":"7033","DOI":"10.7150\/thno.35748","volume":"9","author":"H Yu","year":"2019","unstructured":"Yu H, Li JM, Deng K, Zhou W, Wang CX, Wang Q, et al. Tumor acidity activated triphenylphosphonium-based mitochondrial targeting nanocarriers for overcoming drug resistance of cancer therapy. Theranostics. 2019;9(23):7033\u201350.","journal-title":"Theranostics"},{"key":"4724_CR57","doi-asserted-by":"publisher","first-page":"102928","DOI":"10.1016\/j.nano.2026.102928","volume":"74","author":"Z Xu","year":"2026","unstructured":"Xu Z, Haghighat M, Shafiabady N, Wu R, Sang R, Deng W. Nuclear-targeted CRISPR\/Cas delivery by using aptamer-modified polymer lipid nanoparticles. Nanomedicine. 2026;74:102928.","journal-title":"Nanomedicine"},{"issue":"8","key":"4724_CR58","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1208\/s12249-022-02438-y","volume":"23","author":"D Ulker","year":"2022","unstructured":"Ulker D, Ozyurt R, Erkasap N, Butun V. Magnetic Targeting of 5-Fluorouracil-Loaded Liposome-Nanogels for In Vivo Breast Cancer Therapy and the Cytotoxic Effects on Liver and Kidney. AAPS PharmSciTech. 2022;23(8):289.","journal-title":"AAPS PharmSciTech"},{"issue":"21","key":"4724_CR59","first-page":"5177","volume":"45","author":"Y Fei","year":"2020","unstructured":"Fei Y, Jiang-Pei S, Hai-Zhen C, Jun-Yi S, Xing-Mei X, Zi-Fei J, et al. [Preparation and evaluation of schisandrin B-loaded F127 modified lipid-polymer nanoparticles for inhibition of breast cancer lung metastasis]. Zhongguo Zhong Yao Za Zhi. 2020;45(21):5177\u201383.","journal-title":"Zhongguo Zhong Yao Za Zhi"},{"issue":"18","key":"4724_CR60","doi-asserted-by":"publisher","first-page":"3705","DOI":"10.3390\/polym14183705","volume":"14","author":"SS Imam","year":"2022","unstructured":"Imam SS, Gilani SJ, Bin Jumah MN, Rizwanullah M, Zafar A, Ahmed MM, et al. Harnessing lipid polymer hybrid nanoparticles for enhanced oral bioavailability of thymoquinone: in vitro and in vivo assessments. Polymers (Basel). 2022;14(18):3705. https:\/\/doi.org\/10.3390\/polym14183705.","journal-title":"Polymers (Basel)."},{"key":"4724_CR61","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.jconrel.2016.12.019","volume":"246","author":"C He","year":"2017","unstructured":"He C, Cai P, Li J, Zhang T, Lin L, Abbasi AZ, et al. Blood-brain barrier-penetrating amphiphilic polymer nanoparticles deliver docetaxel for the treatment of brain metastases of triple negative breast cancer. J Control Release. 2017;246:98\u2013109.","journal-title":"J Control Release"},{"issue":"2","key":"4724_CR62","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1016\/j.apsb.2025.12.011","volume":"16","author":"C Shen","year":"2026","unstructured":"Shen C, Zhang M, Lu M, Chang E, Gao Z, Ban W, et al. Machine learning empowered formulation design, optimization and characterization of nanoparticulate drug delivery systems: Current applications, challenges, and future perspectives. Acta Pharm Sinica B. 2026;16(2):665\u201385.","journal-title":"Acta Pharm Sinica B"},{"issue":"1","key":"4724_CR63","doi-asserted-by":"publisher","first-page":"18012","DOI":"10.1038\/s41598-023-43689-4","volume":"13","author":"B Hoseini","year":"2023","unstructured":"Hoseini B, Jaafari MR, Golabpour A, Momtazi-Borojeni AA, Karimi M, Eslami S. Application of ensemble machine learning approach to assess the factors affecting size and polydispersity index of liposomal nanoparticles. Sci Rep. 2023;13(1):18012.","journal-title":"Sci Rep"},{"issue":"1","key":"4724_CR64","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1007\/s13346-024-01625-7","volume":"15","author":"S Dong","year":"2025","unstructured":"Dong S, Yu H, Poupart P, Ho EA. Gaussian processes modeling for the prediction of polymeric nanoparticle formulation design to enhance encapsulation efficiency and therapeutic efficacy. Drug Deliv Transl Res. 2025;15(1):372\u201388.","journal-title":"Drug Deliv Transl Res"},{"issue":"3","key":"4724_CR65","first-page":"100811","volume":"18","author":"R Han","year":"2023","unstructured":"Han R, Ye Z, Zhang Y, Cheng Y, Zheng Y, Ouyang D. Predicting liposome formulations by the integrated machine learning and molecular modeling approaches. Asian J Pharm Sci. 2023;18(3):100811.","journal-title":"Asian J Pharm Sci"},{"issue":"9","key":"4724_CR66","doi-asserted-by":"publisher","first-page":"693","DOI":"10.2174\/1386207322666181218160704","volume":"21","author":"AA \u00d6zt\u00fcrk","year":"2018","unstructured":"\u00d6zt\u00fcrk AA, G\u00fcnd\u00fcz AB, Ozisik O. Supervised Machine Learning Algorithms for Evaluation of Solid Lipid Nanoparticles and Particle Size. Comb Chem High Throughput Screen. 2018;21(9):693\u20139.","journal-title":"Comb Chem High Throughput Screen"},{"issue":"1","key":"4724_CR67","doi-asserted-by":"publisher","first-page":"20765","DOI":"10.1038\/s41598-025-06872-3","volume":"15","author":"S Alqarni","year":"2025","unstructured":"Alqarni S, Huwaimel B. Predicting PLGA nanoparticle size and zeta potential in synthesis for application of drug delivery via machine learning analysis. Sci Rep. 2025;15(1):20765.","journal-title":"Sci Rep"},{"issue":"4","key":"4724_CR68","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1007\/s13346-022-01253-z","volume":"13","author":"J Deng","year":"2023","unstructured":"Deng J, Ye Z, Zheng W, Chen J, Gao H, Wu Z, et al. Machine learning in accelerating microsphere formulation development. Drug Deliv Transl Res. 2023;13(4):966\u201382.","journal-title":"Drug Deliv Transl Res"},{"issue":"1","key":"4724_CR69","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s40580-026-00531-7","volume":"13","author":"S Ha","year":"2026","unstructured":"Ha S, Lee DH, Lee T, Jiang H, Lee HJ, Seo S, et al. Machine learning-driven exosome-mimetic lipid nanoparticles for tumor-specific targeting. Nano Converg. 2026;13(1):2.","journal-title":"Nano Converg"},{"issue":"11","key":"4724_CR70","doi-asserted-by":"publisher","first-page":"100996","DOI":"10.1016\/j.jpha.2024.100996","volume":"14","author":"R Maharjan","year":"2024","unstructured":"Maharjan R, Kim KH, Lee K, Han HK, Jeong SH. Machine learning-driven optimization of mRNA-lipid nanoparticle vaccine quality with XGBoost\/Bayesian method and ensemble model approaches. J Pharm Anal. 2024;14(11):100996.","journal-title":"J Pharm Anal"},{"issue":"2","key":"4724_CR71","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1208\/s12249-025-03051-5","volume":"26","author":"S Patel","year":"2025","unstructured":"Patel S, Kalasariya A, Desai J, Patel M, Patel A, Shah U. Machine Learning-Based Prediction of Drug Solubility in Lipidic Environments: The Sol_ME Tool for Optimizing Lipid-Based Formulations with a Preliminary Apalutamide Case Study. AAPS PharmSciTech. 2025;26(2):50.","journal-title":"AAPS PharmSciTech"},{"issue":"45","key":"4724_CR72","doi-asserted-by":"publisher","first-page":"e2407793","DOI":"10.1002\/adma.202407793","volume":"36","author":"XJ Gao","year":"2024","unstructured":"Gao XJ, Ciura K, Ma Y, Mikolajczyk A, Jagiello K, Wan Y, et al. Toward the Integration of Machine Learning and Molecular Modeling for Designing Drug Delivery Nanocarriers. Adv Mater. 2024;36(45):e2407793.","journal-title":"Adv Mater"},{"key":"4724_CR73","doi-asserted-by":"publisher","first-page":"106562","DOI":"10.1016\/j.ejps.2023.106562","volume":"191","author":"JD Murray","year":"2023","unstructured":"Murray JD, Lange JJ, Bennett-Lenane H, Holm R, Kuentz M, O\u2019Dwyer PJ, et al. Advancing algorithmic drug product development: Recommendations for machine learning approaches in drug formulation. Eur J Pharm Sci. 2023;191:106562.","journal-title":"Eur J Pharm Sci"},{"key":"4724_CR74","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/j.ejpb.2015.04.028","volume":"94","author":"Y Li","year":"2015","unstructured":"Li Y, Abbaspour MR, Grootendorst PV, Rauth AM, Wu XY. Optimization of controlled release nanoparticle formulation of verapamil hydrochloride using artificial neural networks with genetic algorithm and response surface methodology. Eur J Pharm Biopharm. 2015;94:170\u20139.","journal-title":"Eur J Pharm Biopharm"},{"key":"4724_CR75","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.omtn.2018.02.003","volume":"11","author":"AM de Groot","year":"2018","unstructured":"de Groot AM, Thanki K, Gangloff M, Falkenberg E, Zeng X, van Bijnen DCJ, et al. Immunogenicity Testing of Lipidoids In Vitro and In Silico: Modulating Lipidoid-Mediated TLR4 Activation by Nanoparticle Design. Mol Ther Nucleic Acids. 2018;11:159\u201369.","journal-title":"Mol Ther Nucleic Acids"},{"issue":"1","key":"4724_CR76","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1186\/s13046-019-1443-1","volume":"38","author":"V Thakur","year":"2019","unstructured":"Thakur V, Kutty RV. Recent advances in nanotheranostics for triple negative breast cancer treatment. J Exp Clin Cancer Res. 2019;38(1):430.","journal-title":"J Exp Clin Cancer Res"},{"issue":"6","key":"4724_CR77","doi-asserted-by":"publisher","first-page":"524","DOI":"10.3390\/pharmaceutics12060524","volume":"12","author":"S Gadag","year":"2020","unstructured":"Gadag S, Sinha S, Nayak Y, Garg S, Nayak UY. Combination therapy and nanoparticulate systems: smart approaches for the effective treatment of breast cancer. Pharmaceutics. 2020;12(6):524. https:\/\/doi.org\/10.3390\/pharmaceutics12060524.","journal-title":"Pharmaceutics."},{"issue":"6","key":"4724_CR78","doi-asserted-by":"publisher","first-page":"1689","DOI":"10.1021\/acssensors.0c00329","volume":"5","author":"M Alafeef","year":"2020","unstructured":"Alafeef M, Srivastava I, Pan D. Machine Learning for Precision Breast Cancer Diagnosis and Prediction of the Nanoparticle Cellular Internalization. ACS Sens. 2020;5(6):1689\u201398.","journal-title":"ACS Sens"},{"issue":"24","key":"4724_CR79","doi-asserted-by":"publisher","first-page":"16070","DOI":"10.3390\/ijms232416070","volume":"23","author":"R Ali","year":"2022","unstructured":"Ali R, Balamurali M, Varamini P. Deep learning-based artificial intelligence to investigate targeted nanoparticles\u2019 uptake in TNBC cells. Int J Mol Sci. 2022;23(24):16070. https:\/\/doi.org\/10.3390\/ijms232416070.","journal-title":"Int J Mol Sci."},{"issue":"4","key":"4724_CR80","doi-asserted-by":"publisher","first-page":"2619","DOI":"10.1021\/acs.analchem.0c04763","volume":"93","author":"MK Song","year":"2021","unstructured":"Song MK, Chen SX, Hu PP, Huang CZ, Zhou J. Automated Plasmonic Resonance Scattering Imaging Analysis via Deep Learning. Anal Chem. 2021;93(4):2619\u201326.","journal-title":"Anal Chem"},{"issue":"33","key":"4724_CR81","doi-asserted-by":"publisher","first-page":"22378","DOI":"10.1021\/acsnano.4c06953","volume":"18","author":"Z Xi","year":"2024","unstructured":"Xi Z, Yao H, Zhang T, Su Z, Wang B, Feng W, et al. Quantitative Three-Dimensional Imaging Analysis of HfO(2) Nanoparticles in Single Cells via Deep Learning Aided X-ray Nano-Computed Tomography. ACS Nano. 2024;18(33):22378\u201389.","journal-title":"ACS Nano"},{"issue":"1","key":"4724_CR82","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1038\/s44303-024-00007-5","volume":"2","author":"EK Zaluzec","year":"2024","unstructured":"Zaluzec EK, Kenyon E, Volk M, Hayat H, Powell K, Loomis A, et al. Tantalum oxide nanoparticles as versatile and high-resolution X-ray contrast agent for intraductal image-guided ablative procedure in rodent models of breast cancer. Npj Imaging. 2024;2(1):3. https:\/\/doi.org\/10.1038\/s44303-024-00007-5.","journal-title":"Npj Imaging."},{"key":"4724_CR83","doi-asserted-by":"publisher","first-page":"118621","DOI":"10.1016\/j.bios.2026.118621","volume":"304","author":"Y Fang","year":"2026","unstructured":"Fang Y, Huang G, Hao S, Chen B, Hao J, Wang Y, et al. A programmable matrix-robust plasmonic MetaRing biosensor for rapid SERS-based chemotherapeutic response profiling. Biosens Bioelectron. 2026;304:118621.","journal-title":"Biosens Bioelectron"},{"issue":"8","key":"4724_CR84","doi-asserted-by":"publisher","first-page":"6612","DOI":"10.1021\/acsnano.3c12803","volume":"18","author":"X Zhang","year":"2024","unstructured":"Zhang X, Wei X, Wu CX, Men X, Wang J, Bai JJ, et al. Multiplex Profiling of Biomarker and Drug Uptake in Single Cells Using Microfluidic Flow Cytometry and Mass Spectrometry. ACS Nano. 2024;18(8):6612\u201322.","journal-title":"ACS Nano"},{"issue":"12","key":"4724_CR85","doi-asserted-by":"publisher","first-page":"6163","DOI":"10.1016\/j.apsb.2025.10.011","volume":"15","author":"R Wang","year":"2025","unstructured":"Wang R, Zhuang C. Graph neural networks driven acceleration in drug discovery. Acta Pharm Sin B. 2025;15(12):6163\u201377.","journal-title":"Acta Pharm Sin B"},{"issue":"7","key":"4724_CR86","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1007\/s00604-025-07286-8","volume":"192","author":"M Irfan","year":"2025","unstructured":"Irfan M, Habiba U, Maryam A. Next-generation cancer therapeutics: unveiling the potential of liposome-based nanoparticles through bioinformatics. Mikrochim Acta. 2025;192(7):428.","journal-title":"Mikrochim Acta"},{"issue":"8","key":"4724_CR87","doi-asserted-by":"publisher","first-page":"2188","DOI":"10.1016\/j.xphs.2024.02.022","volume":"113","author":"S Zanganeh","year":"2024","unstructured":"Zanganeh S, Firoozpour L, Salavatipour MS, Sardari S, Cohan RA, Mohajel N. Critical Aggregation Concentration Can be a Predictor of Doxorubicin Delivery Performance of Self-Assembling Amphiphilic Peptides with Different Hydrophobic Tails. J Pharm Sci. 2024;113(8):2188\u201397.","journal-title":"J Pharm Sci"},{"issue":"7","key":"4724_CR88","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1021\/acs.accounts.6c00062","volume":"59","author":"M Qin","year":"2026","unstructured":"Qin M, Zhang Z, Zhao Y, Meng H. Enhanced transcytosis and retention (ETR) of drug delivery nanocarrier in solid tumors. Acc Chem Res. 2026;59(7):1284\u201396. https:\/\/doi.org\/10.1021\/acs.accounts.6c00062.","journal-title":"Acc Chem Res."},{"key":"4724_CR89","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1016\/j.jconrel.2021.06.039","volume":"336","author":"Y Tang","year":"2021","unstructured":"Tang Y, Zhang J, He D, Miao W, Liu W, Li Y, et al. GANDA: A deep generative adversarial network conditionally generates intratumoral nanoparticles distribution pixels-to-pixels. J Control Release. 2021;336:336\u201343.","journal-title":"J Control Release"},{"issue":"1","key":"4724_CR90","doi-asserted-by":"publisher","first-page":"6305","DOI":"10.1038\/s41467-024-50619-z","volume":"15","author":"Y Xu","year":"2024","unstructured":"Xu Y, Ma S, Cui H, Chen J, Xu S, Gong F, et al. AGILE platform: a deep learning powered approach to accelerate LNP development for mRNA delivery. Nat Commun. 2024;15(1):6305.","journal-title":"Nat Commun"},{"issue":"6","key":"4724_CR91","doi-asserted-by":"publisher","first-page":"1620","DOI":"10.1016\/j.cell.2026.01.012","volume":"189","author":"Y Xu","year":"2026","unstructured":"Xu Y, Cui H, Pang K, Li G, Gong F, Dong S, et al. LUMI-lab: A foundation model-driven autonomous platform enabling discovery of ionizable lipid designs for mRNA delivery. Cell. 2026;189(6):1620\u2013e3525.","journal-title":"Cell"},{"issue":"1","key":"4724_CR92","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/s42234-025-00173-w","volume":"11","author":"H Bendani","year":"2025","unstructured":"Bendani H, Boumajdi N, Belyamani L, Ibrahimi A. Revolutionizing breast cancer immunotherapy by integrating AI and nanotechnology approaches: review of current applications and future directions. Bioelectron Med. 2025;11(1):13.","journal-title":"Bioelectron Med"},{"key":"4724_CR93","doi-asserted-by":"publisher","unstructured":"Singh D, Singh S, Tandon N. Aptamer-directed siRNA delivery systems for triple-negative breast cancer therapy. Nucleosides, Nucleotides & Nucleic Acids. 2025:1\u201319. https:\/\/doi.org\/10.1080\/15257770.2025.2524468","DOI":"10.1080\/15257770.2025.2524468"},{"key":"4724_CR94","doi-asserted-by":"publisher","first-page":"115604","DOI":"10.1016\/j.addr.2025.115604","volume":"222","author":"M Eftekharifar","year":"2025","unstructured":"Eftekharifar M, Heidari R, Mohaghegh N, Najafabadi AH, Heidari H. Advances in photoactivated carbon-based nanostructured materials for targeted cancer therapy. Adv Drug Deliv Rev. 2025;222:115604.","journal-title":"Adv Drug Deliv Rev"},{"issue":"42","key":"4724_CR95","doi-asserted-by":"publisher","first-page":"15331","DOI":"10.1021\/acs.nanolett.5c04034","volume":"25","author":"X Feng","year":"2025","unstructured":"Feng X, Zhang W, Chang-Hao Tsao S, Shen C, Hu L, Wang Y. Integrated Chemical Array and SERS Profiling of Plasma Small Extracellular Vesicles for Breast Cancer Diagnosis. Nano Lett. 2025;25(42):15331\u20139.","journal-title":"Nano Lett"},{"issue":"12","key":"4724_CR96","doi-asserted-by":"publisher","first-page":"1735","DOI":"10.1080\/17425247.2024.2412823","volume":"21","author":"M Ibrahim","year":"2024","unstructured":"Ibrahim M, Fathalla Z, Fatease AA, Alamri AH, Abdelkader H. Breast cancer epidemiology, diagnostic barriers, and contemporary trends in breast nanotheranostics and mechanisms of targeting. Expert Opin Drug Deliv. 2024;21(12):1735\u201354.","journal-title":"Expert Opin Drug Deliv"},{"issue":"12","key":"4724_CR97","doi-asserted-by":"publisher","first-page":"e2122245119","DOI":"10.1073\/pnas.2122245119","volume":"119","author":"Y Huang","year":"2022","unstructured":"Huang Y, Du S, Liu J, Huang W, Liu W, Zhang M, et al. Diagnosis and prognosis of breast cancer by high-performance serum metabolic fingerprints. Proc Natl Acad Sci U S A. 2022;119(12):e2122245119.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"4724_CR98","doi-asserted-by":"publisher","first-page":"103284","DOI":"10.1016\/j.pdpdt.2023.103284","volume":"41","author":"Z Cheng","year":"2023","unstructured":"Cheng Z, Li H, Chen C, Lv X, Zuo E, Xie X, et al. Application of serum SERS technology based on thermally annealed silver nanoparticle composite substrate in breast cancer. Photodiagnosis Photodyn Ther. 2023;41:103284.","journal-title":"Photodiagnosis Photodyn Ther"},{"issue":"2","key":"4724_CR99","doi-asserted-by":"publisher","first-page":"240","DOI":"10.3390\/antiox12020240","volume":"12","author":"A Kubo","year":"2023","unstructured":"Kubo A, Masugi Y, Hase T, Nagashima K, Kawai Y, Takizawa M, et al. Polysulfide serves as a hallmark of desmoplastic reaction to differentially diagnose ductal carcinoma in situ and invasive breast cancer by SERS imaging. Antioxidants (Basel). 2023;12(2):240. https:\/\/doi.org\/10.3390\/antiox12020240.","journal-title":"Antioxidants (Basel)."},{"issue":"20","key":"4724_CR100","first-page":"11244","volume":"15","author":"H Wan","year":"2023","unstructured":"Wan H, Yang X, Sang G, Ruan Z, Ling Z, Zhang M, et al. CDKN2A was a cuproptosis-related gene in regulating chemotherapy resistance by the MAGE-A family in breast cancer: based on artificial intelligence (AI)-constructed pan-cancer risk model. Aging. 2023;15(20):11244\u201367.","journal-title":"Aging"},{"key":"4724_CR101","doi-asserted-by":"publisher","first-page":"999312","DOI":"10.3389\/fmed.2023.999312","volume":"10","author":"K Wang","year":"2023","unstructured":"Wang K, Zheng C, Xue L, Deng D, Zeng L, Li M, et al. A bibliometric analysis of 16,826 triple-negative breast cancer publications using multiple machine learning algorithms: Progress in the past 17 years. Front Med (Lausanne). 2023;10:999312.","journal-title":"Front Med (Lausanne)"},{"issue":"1","key":"4724_CR102","doi-asserted-by":"publisher","first-page":"42190","DOI":"10.1038\/s41598-025-26145-3","volume":"15","author":"S Fathi-Karkan","year":"2025","unstructured":"Fathi-Karkan S, Rahdar A, Shirzad M. Integrating machine-learning and nanotechnology to quantify pH-modulated oxaliplatin release. Sci Rep. 2025;15(1):42190.","journal-title":"Sci Rep"},{"key":"4724_CR103","doi-asserted-by":"publisher","first-page":"107239","DOI":"10.1016\/j.ejps.2025.107239","volume":"213","author":"Y Ijjeh","year":"2025","unstructured":"Ijjeh Y, Alsarayreh N, Rifai A, Abdelnabi H, Al-Mahamid S, Alqudah DA, et al. Quality by digital design for accelerated sustainable nanomedicine development. Eur J Pharm Sci. 2025;213:107239.","journal-title":"Eur J Pharm Sci"},{"key":"4724_CR104","doi-asserted-by":"publisher","unstructured":"Nematov DD. AI-driven autonomous platforms for nanomaterial discovery and optimization: bridging simulation, synthesis, and in situ characterization. SSRN Preprints. 2025. https:\/\/doi.org\/10.2139\/ssrn.5393137","DOI":"10.2139\/ssrn.5393137"},{"issue":"1","key":"4724_CR105","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1186\/s12943-025-02563-9","volume":"25","author":"A Tiwari","year":"2026","unstructured":"Tiwari A, Widodo, Krisnawati DI, Chen C-Y, Kuo T-R. AI-driven nanomedicine for cancer theranostics. Mol Cancer. 2026;25(1):78.","journal-title":"Mol Cancer"},{"key":"4724_CR106","doi-asserted-by":"publisher","first-page":"19352","DOI":"10.1039\/D1NR06195J","volume":"13","author":"L Liu","year":"2021","unstructured":"Liu L, Bi M, Wang Y-H, Liu J, Jiang X, Xu Z, et al. Artificial intelligence-powered microfluidics for nanomedicine and materials synthesis. Nanoscale. 2021;13:19352\u201366. https:\/\/doi.org\/10.1039\/D1NR06195J.","journal-title":"Nanoscale."},{"key":"4724_CR107","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.jconrel.2023.07.040","volume":"361","author":"WC Chou","year":"2023","unstructured":"Chou WC, Chen Q, Yuan L, Cheng YH, He C, Monteiro-Riviere NA, et al. An artificial intelligence-assisted physiologically-based pharmacokinetic model to predict nanoparticle delivery to tumors in mice. J Control Release. 2023;361:53\u201363.","journal-title":"J Control Release"},{"key":"4724_CR108","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/j.jconrel.2024.08.015","volume":"374","author":"K Mi","year":"2024","unstructured":"Mi K, Chou WC, Chen Q, Yuan L, Kamineni VN, Kuchimanchi Y, et al. Predicting tissue distribution and tumor delivery of nanoparticles in mice using machine learning models. J Control Release. 2024;374:219\u201329.","journal-title":"J Control Release"},{"key":"4724_CR109","doi-asserted-by":"publisher","first-page":"934015","DOI":"10.3389\/fmedt.2022.934015","volume":"4","author":"EM Glass","year":"2022","unstructured":"Glass EM, Kulkarni S, Eng C, Feng S, Malaviya A, Radhakrishnan R. Multiphysics pharmacokinetic model for targeted nanoparticles. Front Med Technol. 2022;4:934015.","journal-title":"Front Med Technol"},{"key":"4724_CR110","doi-asserted-by":"publisher","DOI":"10.1016\/j.compchemeng.2025.109081","volume":"198","author":"S Kulkarni","year":"2025","unstructured":"Kulkarni S, Lin B, Radhakrishnan R. Machine learning enabled multiscale model for nanoparticle margination and physiology based pharmacokinetics. Comput Chem Eng. 2025;198:109081. https:\/\/doi.org\/10.1016\/j.compchemeng.2025.109081.","journal-title":"Comput Chem Eng."},{"issue":"24","key":"4724_CR111","doi-asserted-by":"publisher","first-page":"15995","DOI":"10.3390\/ijms232415664","volume":"23","author":"A Sousa-Junior","year":"2022","unstructured":"Sousa-Junior A, Yang CT, Korangath P, Ivkov R, Bakuzis A. A predictive pharmacokinetic model for immune cell-mediated uptake and retention of nanoparticles in tumors. Int J Mol Sci. 2022;23(24):15995. https:\/\/doi.org\/10.3390\/ijms232415664.","journal-title":"Int J Mol Sci."},{"issue":"2","key":"4724_CR112","doi-asserted-by":"publisher","first-page":"266","DOI":"10.3390\/pharmaceutics14020406","volume":"14","author":"H Zazo","year":"2022","unstructured":"Zazo H, Colino CI, Guti\u00e9rrez-Mill\u00e1n C, Cordero AA, Bartneck M, Lanao JM. Physiologically based pharmacokinetic (PBPK) model of gold nanoparticle-based drug delivery system for stavudine biodistribution. Pharmaceutics. 2022;14(2):266. https:\/\/doi.org\/10.3390\/pharmaceutics14020406.","journal-title":"Pharmaceutics."},{"issue":"3","key":"4724_CR113","doi-asserted-by":"publisher","first-page":"102606","DOI":"10.1016\/j.omtn.2025.102606","volume":"36","author":"G Fiandaca","year":"2025","unstructured":"Fiandaca G, Campanile E, Leonardelli L, Pettin\u00e0 E, Giampiccolo S, Carstens EJ, et al. A multiscale physiologically based pharmacokinetic model to support mRNA-encoded BiTE therapy in cancer treatment. Mol Ther Nucleic Acids. 2025;36(3):102606.","journal-title":"Mol Ther Nucleic Acids"},{"key":"4724_CR114","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1016\/j.actbio.2022.12.057","volume":"158","author":"C Moloney","year":"2023","unstructured":"Moloney C, Roy Chaudhuri T, Spernyak JA, Straubinger RM, Brougham DF. Long-circulating magnetoliposomes as surrogates for assessing pancreatic tumour permeability and nanoparticle deposition. Acta Biomater. 2023;158:611\u201324.","journal-title":"Acta Biomater"},{"issue":"39","key":"4724_CR115","doi-asserted-by":"publisher","first-page":"54608","DOI":"10.1021\/acsami.5c15105","volume":"17","author":"A Ali","year":"2025","unstructured":"Ali A, Wang M, Guo H, Jiang C, Wang Z, Dai X, et al. Triglyceride-Rich Conditions Reshape the Protein Corona and Alter Nanobio Interactions. ACS Appl Mater Interfaces. 2025;17(39):54608\u201322.","journal-title":"ACS Appl Mater Interfaces"},{"key":"4724_CR116","doi-asserted-by":"publisher","DOI":"10.1016\/j.cej.2025.161134","volume":"509","author":"A Guha","year":"2025","unstructured":"Guha A, Sadeghi SA, Kunhiraman HH, Fang F, Wang Q, Rafieioskouei A, et al. AI-driven prediction of cardio-oncology biomarkers through protein corona analysis. Chem Eng J. 2025;509:161134. https:\/\/doi.org\/10.1016\/j.cej.2025.161134.","journal-title":"Chem Eng J."},{"issue":"9","key":"4724_CR117","doi-asserted-by":"publisher","first-page":"2500206","DOI":"10.1002\/smsc.202500206","volume":"5","author":"A Greco","year":"2025","unstructured":"Greco A, Corbo C. Therapeutic Implications of Biomolecular Corona on Lipid Nanoparticle-Based Gene Delivery Systems. Small Sci. 2025;5(9):2500206.","journal-title":"Small Sci"},{"issue":"30","key":"4724_CR118","doi-asserted-by":"publisher","first-page":"9202","DOI":"10.1021\/acs.nanolett.4c01469","volume":"24","author":"Y Niu","year":"2024","unstructured":"Niu Y, Yu Y, Shi X, Fu F, Yang H, Mu Q, et al. In Situ Measurement of Nanoparticle-Blood Protein Adsorption and Its Heterogeneity with Single-Nanoparticle Resolution via Dual Fluorescence Quantification. Nano Lett. 2024;24(30):9202\u201311.","journal-title":"Nano Lett"},{"issue":"9","key":"4724_CR119","doi-asserted-by":"publisher","first-page":"5610","DOI":"10.1039\/D1CP03968G","volume":"24","author":"T Upreti","year":"2022","unstructured":"Upreti T, Wolfe KM, Van Bavel N, Anikovskiy M, Labouta HI. Collagen - a newly discovered major player in protein corona formation on nanoparticles. Phys Chem Chem Phys. 2022;24(9):5610\u20137.","journal-title":"Phys Chem Chem Phys"},{"issue":"23","key":"4724_CR120","doi-asserted-by":"publisher","first-page":"21538","DOI":"10.1021\/acsnano.5c03590","volume":"19","author":"J Cave","year":"2025","unstructured":"Cave J, Christiono A, Schiavone C, Pownall HJ, Cristini V, Staquicini DI, et al. Rational Design of Safer Inorganic Nanoparticles via Mechanistic Modeling-Informed Machine Learning. ACS Nano. 2025;19(23):21538\u201355.","journal-title":"ACS Nano"},{"key":"4724_CR121","doi-asserted-by":"publisher","first-page":"144381","DOI":"10.1016\/j.chemosphere.2025.144381","volume":"378","author":"M Nedkyalkova","year":"2025","unstructured":"Nedkyalkova M, Vasighi M, Lattuada M. Integrating surface chemistry properties and machine learning to map the toxicity landscape of superparamagnetic iron oxide nanoparticles. Chemosphere. 2025;378:144381.","journal-title":"Chemosphere"},{"issue":"11","key":"4724_CR122","doi-asserted-by":"publisher","first-page":"6703","DOI":"10.1021\/acs.molpharmaceut.5c00661","volume":"22","author":"E Yildirim","year":"2025","unstructured":"Yildirim E, Cakir I, Ileri-Ercan N. Machine Learning Analysis of Cytotoxicity Determinants in Nanoparticle-Based Rheumatoid Arthritis Therapies. Mol Pharm. 2025;22(11):6703\u201313.","journal-title":"Mol Pharm"},{"issue":"9","key":"4724_CR123","doi-asserted-by":"publisher","first-page":"1400","DOI":"10.1080\/15376516.2025.2538128","volume":"35","author":"B Alabi","year":"2025","unstructured":"Alabi B, Lawal SK, Olojede SO, Suleiman A, Adesanya O, Ochuole DO, et al. In silico and in vivo toxicity assessment of cysteamine-modified nanoparticles: implications for pharmacotherapy application. Toxicol Mech Methods. 2025;35(9):1400\u201318.","journal-title":"Toxicol Mech Methods"},{"issue":"4","key":"4724_CR124","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1080\/17435390.2022.2106906","volume":"16","author":"E Di Ianni","year":"2022","unstructured":"Di Ianni E, M\u00f8ller P, Cholakova T, Wolff H, Jacobsen NR, Vogel U. Assessment of primary and inflammation-driven genotoxicity of carbon black nanoparticles in vitro and in vivo. Nanotoxicology. 2022;16(4):526\u201346.","journal-title":"Nanotoxicology"},{"issue":"41","key":"4724_CR125","doi-asserted-by":"publisher","first-page":"17615","DOI":"10.1039\/D1NR04460E","volume":"13","author":"S Kelly","year":"2021","unstructured":"Kelly S, Byrne MH, Quinn SJ, Simpson JC. Multiparametric nanoparticle-induced toxicity readouts with single cell resolution in HepG2 multicellular tumour spheroids. Nanoscale. 2021;13(41):17615\u201328.","journal-title":"Nanoscale"},{"issue":"9","key":"4724_CR126","doi-asserted-by":"publisher","first-page":"2157","DOI":"10.1007\/s13346-022-01170-1","volume":"12","author":"MA Tutty","year":"2022","unstructured":"Tutty MA, Vella G, Prina-Mello A. Pre-clinical 2D and 3D toxicity response to a panel of nanomaterials; comparative assessment of NBM-induced liver toxicity. Drug Deliv Transl Res. 2022;12(9):2157\u201377.","journal-title":"Drug Deliv Transl Res"},{"issue":"1","key":"4724_CR127","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1186\/s12989-021-00433-y","volume":"18","author":"TH Shin","year":"2021","unstructured":"Shin TH, Manavalan B, Lee DY, Basith S, Seo C, Paik MJ, et al. Silica-coated magnetic-nanoparticle-induced cytotoxicity is reduced in microglia by glutathione and citrate identified using integrated omics. Part Fibre Toxicol. 2021;18(1):42.","journal-title":"Part Fibre Toxicol"},{"issue":"5","key":"4724_CR128","doi-asserted-by":"publisher","first-page":"354","DOI":"10.3390\/toxics12050354","volume":"12","author":"A Ramovi\u0107 Hamzagi\u0107","year":"2024","unstructured":"Ramovi\u0107 Hamzagi\u0107 A, Gazdi\u0107 Jankovi\u0107 M, Cvetkovi\u0107 D, Nikoli\u0107 D, Nikoli\u0107 S, Milivojevi\u0107 Dimitrijevi\u0107 N, et al. Machine learning model for prediction of development of cancer stem cell subpopulation in tumurs subjected to polystyrene nanoparticles. Toxics. 2024;12(5):354. https:\/\/doi.org\/10.3390\/toxics12050354.","journal-title":"Toxics."},{"issue":"17","key":"4724_CR129","doi-asserted-by":"publisher","first-page":"1354","DOI":"10.3390\/nano15171354","volume":"15","author":"A Abughalia","year":"2025","unstructured":"Abughalia A, Flynn M, Clarke PFA, Fayne D, Gobbo OL. The use of computational approaches to design nanodelivery systems. Nanomaterials (Basel). 2025;15(17):1354. https:\/\/doi.org\/10.3390\/nano15171354.","journal-title":"Nanomaterials (Basel)."},{"issue":"12","key":"4724_CR130","doi-asserted-by":"publisher","first-page":"1819","DOI":"10.1080\/03639045.2025.2569573","volume":"51","author":"A Rastegari","year":"2025","unstructured":"Rastegari A, Faghihi H, Mobinikhaledi M. Prediction drug release profile from chitosan nanoparticles: integration of experimental data and machine learning models. Drug Dev Ind Pharm. 2025;51(12):1819\u201327.","journal-title":"Drug Dev Ind Pharm"},{"issue":"7","key":"4724_CR131","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1080\/17425247.2025.2502022","volume":"22","author":"M Akhtar","year":"2025","unstructured":"Akhtar M, Nehal N, Gull A, Parveen R, Khan S, Khan S, et al. Explicating the transformative role of artificial intelligence in designing targeted nanomedicine. Expert Opin Drug Deliv. 2025;22(7):971\u201391.","journal-title":"Expert Opin Drug Deliv"},{"issue":"3","key":"4724_CR132","doi-asserted-by":"publisher","first-page":"104633","DOI":"10.1016\/j.drudis.2026.104633","volume":"31","author":"D Esmaeilpour","year":"2026","unstructured":"Esmaeilpour D, Ghavami S, Zarrabi A, Khosravi A, Zarepour A, Cordani M, et al. Artificial-intelligence-guided autophagy modulation and nanomedicine design for precision photodynamic cancer therapy. Drug Discov Today. 2026;31(3):104633.","journal-title":"Drug Discov Today"},{"issue":"1","key":"4724_CR133","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1186\/s12951-025-03850-9","volume":"23","author":"Y Jang","year":"2025","unstructured":"Jang Y, Babu A, Chahal S, Vasukutty A, J JM, Park IK, et al. AI-guided design of a CXCR4-targeted core-shell nanocarrier for co-delivery of berberine\/paclitaxel in cancer therapy. J Nanobiotechnol. 2025;23(1):773.","journal-title":"J Nanobiotechnol"},{"issue":"34","key":"4724_CR134","doi-asserted-by":"publisher","first-page":"4224","DOI":"10.2174\/0929867324666170830113755","volume":"25","author":"S Palazzolo","year":"2018","unstructured":"Palazzolo S, Bayda S, Hadla M, Caligiuri I, Corona G, Toffoli G, et al. The Clinical Translation of Organic Nanomaterials for Cancer Therapy: A Focus on Polymeric Nanoparticles, Micelles, Liposomes and Exosomes. Curr Med Chem. 2018;25(34):4224\u201368.","journal-title":"Curr Med Chem"},{"issue":"13","key":"4724_CR135","doi-asserted-by":"publisher","first-page":"2601","DOI":"10.3390\/polym14132601","volume":"14","author":"V Ejigah","year":"2022","unstructured":"Ejigah V, Owoseni O, Bataille-Backer P, Ogundipe OD, Fisusi FA, Adesina SK. Approaches to improve macromolecule and nanoparticle accumulation in the tumor microenvironment by the enhanced permeability and retention effect. Polymers. 2022;14(13):2601. https:\/\/doi.org\/10.3390\/polym14132601.","journal-title":"Polymers."},{"issue":"20","key":"4724_CR136","doi-asserted-by":"publisher","first-page":"19810","DOI":"10.1021\/acsnano.3c04037","volume":"17","author":"Q Chen","year":"2023","unstructured":"Chen Q, Yuan L, Chou WC, Cheng YH, He C, Monteiro-Riviere NA, et al. Meta-Analysis of Nanoparticle Distribution in Tumors and Major Organs in Tumor-Bearing Mice. ACS Nano. 2023;17(20):19810\u201331.","journal-title":"ACS Nano"},{"key":"4724_CR137","doi-asserted-by":"publisher","first-page":"100208","DOI":"10.1016\/j.mtbio.2022.100208","volume":"13","author":"M Souri","year":"2022","unstructured":"Souri M, Soltani M, Moradi Kashkooli F, Kiani Shahvandi M, Chiani M, Shariati FS, et al. Towards principled design of cancer nanomedicine to accelerate clinical translation. Mater Today Bio. 2022;13:100208.","journal-title":"Mater Today Bio"},{"issue":"15","key":"4724_CR138","doi-asserted-by":"publisher","first-page":"14605","DOI":"10.1021\/acsnano.5c00484","volume":"19","author":"MJ Baek","year":"2025","unstructured":"Baek MJ, Hur W, Kashiwagi S, Choi HS. Design Considerations for Organ-Selective Nanoparticles. ACS Nano. 2025;19(15):14605\u201326.","journal-title":"ACS Nano"},{"issue":"11","key":"4724_CR139","doi-asserted-by":"publisher","first-page":"5698","DOI":"10.1039\/D3CS00912B","volume":"54","author":"Z Li","year":"2025","unstructured":"Li Z, Xiao C, Yang X, Li Z. Progress in the mechanical properties of nanoparticles for tumor-targeting delivery. Chem Soc Rev. 2025;54(11):5698\u2013734.","journal-title":"Chem Soc Rev"},{"issue":"4","key":"4724_CR140","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1080\/20415990.2026.2662808","volume":"17","author":"D Singh","year":"2026","unstructured":"Singh D, Bhattacharya S. Drug-carrier molecular incompatibility as a hidden determinant of failure in cancer nanomedicine: investigation of possible solutions. Ther Deliv. 2026;17(4):337\u201355. https:\/\/doi.org\/10.1080\/20415990.2026.2662808.","journal-title":"Ther Deliv."},{"issue":"10","key":"4724_CR141","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202103745","volume":"9","author":"I Biancacci","year":"2022","unstructured":"Biancacci I, De Lorenzi F, Theek B, Bai X, May JN, Consolino L, et al. Monitoring EPR effect dynamics during nanotaxane treatment with theranostic polymeric micelles. Advanced Science. 2022;9(10):e2103745.","journal-title":"Advanced Science"},{"issue":"6","key":"4724_CR142","doi-asserted-by":"publisher","first-page":"560","DOI":"10.2174\/1389450116666150202163022","volume":"16","author":"LW Dobrucki","year":"2015","unstructured":"Dobrucki LW, Pan D, Smith AM. Multiscale imaging of nanoparticle drug delivery. Curr Drug Targets. 2015;16(6):560\u201370.","journal-title":"Curr Drug Targets"},{"key":"4724_CR143","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2022.114528","volume":"189","author":"J Momoh","year":"2022","unstructured":"Momoh J, Kapsokalyvas D, Vogt M, Hak S, Kiessling F, van Zandvoort M, et al. Intravital microscopy for real-time monitoring of drug delivery and nanobiological processes. Adv Drug Deliv Rev. 2022;189:114528.","journal-title":"Adv Drug Deliv Rev"},{"key":"4724_CR144","doi-asserted-by":"publisher","DOI":"10.2147\/IJN.S559763","volume":"21","author":"L Chen","year":"2026","unstructured":"Chen L, Deng X, Shen Q, Chen M, Li C, Wang S. Novel dual strategy based on EPR\/AT for optimizing therapeutic effect by improving drug delivery system physicochemical properties and regulating TME. Int J Nanomedicine. 2026;21:559763.","journal-title":"Int J Nanomedicine"},{"issue":"7","key":"4724_CR145","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1080\/1354750X.2025.2591717","volume":"30","author":"A Yasmin","year":"2025","unstructured":"Yasmin A, Jha R, Passi A, Saha P, Goyal J, Jindal S, et al. Emerging biomarkers in breast cancer: translational and multi-omics perspectives in precision oncology. Biomarkers. 2025;30(7):516\u201340.","journal-title":"Biomarkers"},{"issue":"1","key":"4724_CR146","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1038\/s41392-023-01536-y","volume":"8","author":"D Fan","year":"2023","unstructured":"Fan D, Cao Y, Cao M, Wang Y, Cao Y, Gong T. Nanomedicine in cancer therapy. Signal Transduction and Targeted Therapy. 2023;8(1):293. https:\/\/doi.org\/10.1038\/s41392-023-01536-y","journal-title":"Signal Transduction and Targeted Therapy"},{"issue":"1","key":"4724_CR147","doi-asserted-by":"publisher","DOI":"10.1002\/wnan.1519","volume":"11","author":"YR Zhang","year":"2019","unstructured":"Zhang YR, Lin R, Li HJ, He WL, Du JZ, Wang J. Strategies to improve tumor penetration of nanomedicines through nanoparticle design. WIREs Nanomedicine and Nanobiotechnology. 2019;11(1):e1519.","journal-title":"WIREs Nanomedicine and Nanobiotechnology"},{"key":"4724_CR148","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.biomaterials.2015.05.006","volume":"60","author":"S Ruan","year":"2015","unstructured":"Ruan S, Cao X, Cun X, Hu G, Zhou Y, Zhang Y, et al. Matrix metalloproteinase-sensitive size-shrinkable nanoparticles for deep tumor penetration and pH triggered doxorubicin release. Biomaterials. 2015;60:100\u201310.","journal-title":"Biomaterials"},{"issue":"2","key":"4724_CR149","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1016\/j.apsb.2024.12.016","volume":"15","author":"H Nie","year":"2025","unstructured":"Nie H, Huang R, Jiang G, Li W, Yang L, Zhang M, et al. Modulating active targeting nanoparticle design according to tumor progressions. Acta Pharm Sin B. 2025;15(2):1143\u201358.","journal-title":"Acta Pharm Sin B"},{"issue":"41","key":"4724_CR150","first-page":"e2308639","volume":"20","author":"R Wang","year":"2024","unstructured":"Wang R, Kumar P, Reda M, Wallstrum AG, Crumrine NA, Ngamcherdtrakul W, et al. Nanotechnology Applications in Breast Cancer Immunotherapy. Small. 2024;20(41):e2308639.","journal-title":"Small"},{"issue":"17","key":"4724_CR151","doi-asserted-by":"publisher","first-page":"9952","DOI":"10.3390\/ijms23179952","volume":"23","author":"AJA Freitas","year":"2022","unstructured":"Freitas AJA, Causin RL, Varuzza MB, Calfa S, Hidalgo Filho CMT, Komoto TT, et al. Liquid biopsy as a tool for the diagnosis, treatment, and monitoring of breast cancer. Int J Mol Sci. 2022;23(17):9952. https:\/\/doi.org\/10.3390\/ijms23179952.","journal-title":"Int J Mol Sci."},{"issue":"2","key":"4724_CR152","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/j.annonc.2020.11.007","volume":"32","author":"MJM Magbanua","year":"2021","unstructured":"Magbanua MJM, Swigart LB, Wu HT, Hirst GL, Yau C, Wolf DM, et al. Circulating tumor DNA in neoadjuvant-treated breast cancer reflects response and survival. Ann Oncol. 2021;32(2):229\u201339.","journal-title":"Ann Oncol"},{"issue":"13","key":"4724_CR153","doi-asserted-by":"publisher","first-page":"e1901989","DOI":"10.1002\/adma.201901989","volume":"32","author":"O Adir","year":"2020","unstructured":"Adir O, Poley M, Chen G, Froim S, Krinsky N, Shklover J, et al. Integrating Artificial Intelligence and Nanotechnology for Precision Cancer Medicine. Adv Mater. 2020;32(13):e1901989.","journal-title":"Adv Mater"},{"issue":"30","key":"4724_CR154","doi-asserted-by":"publisher","first-page":"e03138","DOI":"10.1002\/advs.202503138","volume":"12","author":"Q Wang","year":"2025","unstructured":"Wang Q, Liu Y, Li C, Xu B, Xu S, Liu B. Machine Learning-Enhanced Nanoparticle Design for Precision Cancer Drug Delivery. Adv Sci (Weinh). 2025;12(30):e03138.","journal-title":"Adv Sci (Weinh)"},{"issue":"4","key":"4724_CR155","doi-asserted-by":"publisher","first-page":"e70027","DOI":"10.1002\/wnan.70027","volume":"17","author":"WC Chou","year":"2025","unstructured":"Chou WC, Canchola A, Zhang F, Lin Z. Machine Learning and Artificial Intelligence in Nanomedicine. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2025;17(4):e70027.","journal-title":"Wiley Interdiscip Rev Nanomed Nanobiotechnol"},{"issue":"1","key":"4724_CR156","doi-asserted-by":"publisher","first-page":"124","DOI":"10.3390\/s26010124","volume":"26","author":"P Nguyen","year":"2025","unstructured":"Nguyen P, Kim M, Nichols E, Yoon HS. AI-driven digital twins for manufacturing: a review across hierarchical manufacturing system levels. Sensors. 2025;26(1):124. https:\/\/doi.org\/10.3390\/s26010124.","journal-title":"Sensors."},{"issue":"8","key":"4724_CR157","doi-asserted-by":"publisher","first-page":"992","DOI":"10.3390\/pharmaceutics17080992","volume":"17","author":"R Bhujel","year":"2025","unstructured":"Bhujel R, Enkmann V, Burgstaller H, Maharjan R. Artificial intelligence-driven strategies for targeted delivery and enhanced stability of RNA-based lipid nanoparticle cancer vaccines. Pharmaceutics. 2025;17(8):992. https:\/\/doi.org\/10.3390\/pharmaceutics17080992.","journal-title":"Pharmaceutics."},{"issue":"12","key":"4724_CR158","doi-asserted-by":"publisher","first-page":"2076","DOI":"10.3390\/mi13122076","volume":"13","author":"S Cai","year":"2022","unstructured":"Cai S, Erfle P, Dietzel A. A digital twin of the coaxial lamination mixer for the systematic study of mixing performance and the prediction of precipitated nanoparticle properties. Micromachines (Basel). 2022;13(12):2076. https:\/\/doi.org\/10.3390\/mi13122076.","journal-title":"Micromachines (Basel)."},{"key":"4724_CR159","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1007\/978-1-0716-3770-8_16","volume":"2786","author":"A Nair","year":"2024","unstructured":"Nair A, Loveday KA, Kenyon C, Qu J, Kis Z. Quality by Digital Design for Developing Platform RNA Vaccine and Therapeutic Manufacturing Processes. Methods Mol Biol. 2024;2786:339\u201364.","journal-title":"Methods Mol Biol"},{"key":"4724_CR160","doi-asserted-by":"publisher","first-page":"126301","DOI":"10.1016\/j.ijpharm.2025.126301","volume":"686","author":"MA Shahab","year":"2025","unstructured":"Shahab MA, Stover NM, Al-Mahayni H, Srisuma P, Wang J, Shin S, et al. End-to-end digital twin software for continuous mRNA manufacturing. Int J Pharm. 2025;686:126301.","journal-title":"Int J Pharm"},{"issue":"7","key":"4724_CR161","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1080\/17435889.2025.2457930","volume":"20","author":"I Ottonelli","year":"2025","unstructured":"Ottonelli I, Baraldi C, Ruozi B, Vandelli MA, Tosi G, Duskey JT. Advantages and challenges of polymer-lipid hybrid nanoparticles for the delivery of biotech drugs. Nanomedicine. 2025;20(7):641\u20133.","journal-title":"Nanomedicine"},{"issue":"2","key":"4724_CR162","doi-asserted-by":"publisher","first-page":"C343","DOI":"10.1152\/ajpcell.00109.2021","volume":"321","author":"KM Turner","year":"2021","unstructured":"Turner KM, Yeo SK, Holm TM, Shaughnessy E, Guan JL. Heterogeneity within molecular subtypes of breast cancer. Am J Physiol Cell Physiol. 2021;321(2):C343\u201354.","journal-title":"Am J Physiol Cell Physiol"},{"issue":"1","key":"4724_CR163","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/s40580-025-00502-4","volume":"12","author":"H Li","year":"2025","unstructured":"Li H, Zhao Y, Xu C. Machine learning techniques for lipid nanoparticle formulation. Nano Converg. 2025;12(1):35.","journal-title":"Nano Converg"},{"issue":"1","key":"4724_CR164","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1186\/s12951-025-03677-4","volume":"23","author":"J Zeng","year":"2025","unstructured":"Zeng J, Tang X, Qin D, Yu L, Zhou X, Feng C, et al. Engineered GLP-1R-targeting nanoplatforms: multimodal therapeutics in human diseases. J Nanobiotechnol. 2025;23(1):682.","journal-title":"J Nanobiotechnol"},{"key":"4724_CR165","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2025.114138","volume":"386","author":"F Moradi Kashkooli","year":"2025","unstructured":"Moradi Kashkooli F, Bhandari A, Gu B, Kolios MC, Kohandel M, Zhan W. Multiphysics modelling enhanced by imaging and artificial intelligence for personalised cancer nanomedicine: foundations for clinical digital twins. Journal of Controlled Release. 2025;386:114138.","journal-title":"Journal of Controlled Release"},{"issue":"10","key":"4724_CR166","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1038\/nnano.2012.168","volume":"7","author":"PM Valencia","year":"2012","unstructured":"Valencia PM, Farokhzad OC, Karnik R, Langer R. Microfluidic technologies for accelerating the clinical translation of nanoparticles. Nat Nanotechnol. 2012;7(10):623\u20139.","journal-title":"Nat Nanotechnol"},{"issue":"2","key":"4724_CR167","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1021\/acsbiomaterials.4c02052","volume":"11","author":"K Chen","year":"2025","unstructured":"Chen K, Yang H, Cai R. Microfluidics for nanomedicine delivery. ACS Biomater Sci Eng. 2025;11(2):774\u201383.","journal-title":"ACS Biomater Sci Eng"},{"key":"4724_CR168","doi-asserted-by":"publisher","first-page":"114192","DOI":"10.1016\/j.jconrel.2025.114192","volume":"387","author":"M Abdelkarim","year":"2025","unstructured":"Abdelkarim M, Abostait A, Czitrom S, McColman S, Ahmed I, Wong CCW, et al. Hydrodynamic focusing to synthesize lipid-based nanoparticles: Computational and experimental analysis of chip design and formulation parameters. J Control Release. 2025;387:114192.","journal-title":"J Control Release"},{"issue":"9","key":"4724_CR169","doi-asserted-by":"publisher","first-page":"2906","DOI":"10.1021\/nl801736q","volume":"8","author":"R Karnik","year":"2008","unstructured":"Karnik R, Gu F, Basto P, Cannizzaro C, Dean L, Kyei-Manu W, et al. Microfluidic platform for controlled synthesis of polymeric nanoparticles. Nano Lett. 2008;8(9):2906\u201312.","journal-title":"Nano Lett"},{"issue":"2","key":"4724_CR170","doi-asserted-by":"publisher","first-page":"438","DOI":"10.3390\/biomedicines10020438","volume":"10","author":"F Roffo","year":"2022","unstructured":"Roffo F, Ponsiglione AM, Netti PA, Torino E. Coupled hydrodynamic flow focusing (cHFF) to engineer lipid-polymer nanoparticles (LiPoNs) for multimodal imaging and theranostic applications. Biomedicines. 2022;10(2):438. https:\/\/doi.org\/10.3390\/biomedicines10020438.","journal-title":"Biomedicines."},{"issue":"8","key":"4724_CR171","doi-asserted-by":"publisher","first-page":"1596","DOI":"10.1039\/D2SM01443B","volume":"19","author":"N Kambar","year":"2023","unstructured":"Kambar N, Leal C. Microfluidic synthesis of multilayered lipid-polymer hybrid nanoparticles for the formulation of low solubility drugs. Soft Matter. 2023;19(8):1596\u2013605.","journal-title":"Soft Matter"},{"key":"4724_CR172","doi-asserted-by":"publisher","first-page":"125973","DOI":"10.1016\/j.ijpharm.2025.125973","volume":"682","author":"M Biscaia-Caleiras","year":"2025","unstructured":"Biscaia-Caleiras M, Lopes D, Henriques C, Louren\u00e7o AS, Nunes A, Ba\u00f1obre M, et al. Integrating microfluidics and streamlined remote drug loading: one step closer to continuous manufacturing of liposomal injectables containing small drugs. Int J Pharm. 2025;682:125973.","journal-title":"Int J Pharm"},{"issue":"33","key":"4724_CR173","doi-asserted-by":"publisher","first-page":"e2303567120","DOI":"10.1073\/pnas.2303567120","volume":"120","author":"SJ Shepherd","year":"2023","unstructured":"Shepherd SJ, Han X, Mukalel AJ, El-Mayta R, Thatte AS, Wu J, et al. Throughput-scalable manufacturing of SARS-CoV-2 mRNA lipid nanoparticle vaccines. Proc Natl Acad Sci U S A. 2023;120(33):e2303567120.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"4724_CR174","first-page":"100399","volume":"10","author":"MJ Javid-Naderi","year":"2025","unstructured":"Javid-Naderi MJ, Mousavi Shaegh SA. Advanced microfluidic techniques for the preparation of solid lipid nanoparticles: Innovations and biomedical applications. Int J Pharm X. 2025;10:100399.","journal-title":"Int J Pharm X"},{"issue":"23","key":"4724_CR175","doi-asserted-by":"publisher","first-page":"e2400946","DOI":"10.1002\/adhm.202400946","volume":"13","author":"DRS Almeida","year":"2024","unstructured":"Almeida DRS, Gil JF, Guillot AJ, Li J, Pinto RJB, Santos HA, et al. Advances in Microfluidic-Based Core@Shell Nanoparticles Fabrication for Cancer Applications. Adv Healthc Mater. 2024;13(23):e2400946.","journal-title":"Adv Healthc Mater"},{"issue":"29","key":"4724_CR176","doi-asserted-by":"publisher","first-page":"41666","DOI":"10.1021\/acsami.5c06927","volume":"17","author":"M Maeki","year":"2025","unstructured":"Maeki M, Niwa A, Oyama S, Aratani K, Ito R, Suzuki Y, et al. Microfluidic Production of Exosome-Mimicking Lipid Nanoparticles for Enhanced RNA Delivery: Role of Exosomal Proteins. ACS Appl Mater Interfaces. 2025;17(29):41666\u201379.","journal-title":"ACS Appl Mater Interfaces"},{"issue":"6","key":"4724_CR177","doi-asserted-by":"publisher","first-page":"oyaf101","DOI":"10.1093\/oncolo\/oyaf101","volume":"30","author":"L Tang","year":"2025","unstructured":"Tang L, He M, Geng C, Fan Z, Ling R, Qiao G, et al. Pegylated liposomal doxorubicin + cyclophosphamide followed by taxane as adjuvant therapy for early-stage breast cancer: a randomized controlled trial. The Oncologist. 2025;30(6):oyaf101. https:\/\/doi.org\/10.1093\/oncolo\/oyaf101.","journal-title":"The Oncologist."},{"issue":"10","key":"4724_CR178","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1159\/000540369","volume":"47","author":"LM Tseng","year":"2024","unstructured":"Tseng LM, Chen FM, Chen ST, Cheng FT, Chao TY, Dai MS, et al. Comparison of the Efficacy, Safety, and Quality of Life of Pegylated Liposomal Doxorubicin-Cyclophosphamide versus Epirubicin-Cyclophosphamide in Patients with Early-Stage HER2-Negative Breast Cancer: A Prospective, Randomized, Multicenter, Phase II Study. Oncol Res Treat. 2024;47(10):484\u201395.","journal-title":"Oncol Res Treat"},{"issue":"6","key":"4724_CR179","doi-asserted-by":"publisher","first-page":"5167","DOI":"10.3390\/curroncol28060433","volume":"28","author":"S Dellapasqua","year":"2021","unstructured":"Dellapasqua S, Trillo Aliaga P, Munzone E, Bagnardi V, Pagan E, Montagna E, et al. Pegylated Liposomal Doxorubicin (Caelyx(\u00ae)) as Adjuvant Treatment in Early-Stage Luminal B-like Breast Cancer: A Feasibility Phase II Trial. Curr Oncol. 2021;28(6):5167\u201378.","journal-title":"Curr Oncol"},{"key":"4724_CR180","doi-asserted-by":"publisher","first-page":"116161","DOI":"10.1016\/j.ejca.2025.116161","volume":"233","author":"MR Borrego","year":"2026","unstructured":"Borrego MR, L\u00f3pez-Bravo DP, Vila MM, P\u00e9rez-Garc\u00eda JM, Fern\u00e1ndez M, Tormo SB, et al. Liposomal irinotecan in patients with HER2-negative breast cancer and brain metastases: The PHENOMENAL phase 2 study. Eur J Cancer. 2026;233:116161.","journal-title":"Eur J Cancer"},{"issue":"1","key":"4724_CR181","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1038\/s41467-024-55090-4","volume":"16","author":"Y Fan","year":"2025","unstructured":"Fan Y, Zhang Q, Yan M, Qu X, Yin Y, Sun T, et al. Intravenous liposomal irinotecan in metastatic triple-negative breast cancer after \u2265\u20092 prior lines of chemotherapy: a phase Ib study. Nat Commun. 2025;16(1):3.","journal-title":"Nat Commun"},{"issue":"3","key":"4724_CR182","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1007\/s10549-020-05995-7","volume":"185","author":"JC Sachdev","year":"2021","unstructured":"Sachdev JC, Munster P, Northfelt DW, Han HS, Ma C, Maxwell F, et al. Phase I study of liposomal irinotecan in patients with metastatic breast cancer: findings from the expansion phase. Breast Cancer Res Treat. 2021;185(3):759\u201371.","journal-title":"Breast Cancer Res Treat"},{"issue":"1","key":"4724_CR183","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1007\/s10549-023-06894-3","volume":"199","author":"H Jiang","year":"2023","unstructured":"Jiang H, Li H, Song G, Di L, Shao B, Yan Y, et al. Pegylated liposomal doxorubicin (Duomeisu(\u00ae)) monotherapy in patients with HER2-negative metastatic breast cancer heavily pretreated with anthracycline and taxanes: a single-arm, phase II study. Breast Cancer Res Treat. 2023;199(1):67\u201379.","journal-title":"Breast Cancer Res Treat"},{"issue":"22","key":"4724_CR184","doi-asserted-by":"publisher","first-page":"1631","DOI":"10.2217\/fon-2019-0742","volume":"16","author":"A Fabi","year":"2020","unstructured":"Fabi A, Ferretti G, Malaguti P, Gasparro S, Nistic\u00f2 C, Arpino G, et al. Nanoparticle Albumin-Bound Paclitaxel\/Liposomal-Encapsulated Doxorubicin in HER2-Negative Metastatic Breast Cancer Patients. Future Oncol. 2020;16(22):1631\u20139.","journal-title":"Future Oncol"},{"issue":"1","key":"4724_CR185","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-007990","volume":"12","author":"NK Andresen","year":"2024","unstructured":"Andresen NK, R\u00f8ssevold AH, Quaghebeur C, Gilje B, Boge B, Gombos A, et al. Ipilimumab and nivolumab combined with anthracycline-based chemotherapy in metastatic hormone receptor-positive breast cancer: a randomized phase 2b trial. J Immunother Cancer. 2024;12(1): e007990. https:\/\/doi.org\/10.1136\/jitc-2023-007990.","journal-title":"J Immunother Cancer"},{"issue":"12","key":"4724_CR186","doi-asserted-by":"publisher","first-page":"2573","DOI":"10.1038\/s41591-022-02126-1","volume":"28","author":"AH R\u00f8ssevold","year":"2022","unstructured":"R\u00f8ssevold AH, Andresen NK, Bjerre CA, Gilje B, Jakobsen EH, Raj SX, et al. Atezolizumab plus anthracycline-based chemotherapy in metastatic triple-negative breast cancer: the randomized, double-blind phase 2b ALICE trial. Nat Med. 2022;28(12):2573\u201383.","journal-title":"Nat Med"},{"issue":"1","key":"4724_CR187","doi-asserted-by":"publisher","first-page":"e15","DOI":"10.1093\/oncolo\/oyad160","volume":"29","author":"JX Yang","year":"2024","unstructured":"Yang JX, Yang YQ, Hu WY, Yang L, Wu J, Wen XX, et al. A Phase II Study of Neoadjuvant PLD\/Cyclophosphamide and Sequential nab-Paclitaxel Plus Dual HER2 Blockade in HER2-Positive Breast Cancer. Oncologist. 2024;29(1):e15\u201324.","journal-title":"Oncologist"},{"issue":"1","key":"4724_CR188","doi-asserted-by":"publisher","first-page":"3705","DOI":"10.1038\/s41598-023-30950-z","volume":"13","author":"C Mamot","year":"2023","unstructured":"Mamot C, Wicki A, Hasler-Strub U, Riniker S, Li Q, Holer L, et al. A multicenter phase II trial of anti-EGFR-immunoliposomes loaded with doxorubicin in patients with advanced triple negative breast cancer. Sci Rep. 2023;13(1):3705.","journal-title":"Sci Rep"},{"issue":"5","key":"4724_CR189","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1038\/s41416-019-0391-z","volume":"120","author":"Y Fujiwara","year":"2019","unstructured":"Fujiwara Y, Mukai H, Saeki T, Ro J, Lin YC, Nagai SE, et al. A multi-national, randomised, open-label, parallel, phase III non-inferiority study comparing NK105 and paclitaxel in metastatic or recurrent breast cancer patients. Br J Cancer. 2019;120(5):475\u201380.","journal-title":"Br J Cancer"},{"key":"4724_CR190","doi-asserted-by":"publisher","first-page":"4567","DOI":"10.2147\/IJN.S372477","volume":"17","author":"Y Kosaka","year":"2022","unstructured":"Kosaka Y, Saeki T, Takano T, Aruga T, Yamashita T, Masuda N, et al. Multicenter Randomized Open-Label Phase II Clinical Study Comparing Outcomes of NK105 and Paclitaxel in Advanced or Recurrent Breast Cancer. Int J Nanomed. 2022;17:4567\u201378.","journal-title":"Int J Nanomed"},{"issue":"2","key":"4724_CR191","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1007\/s10637-021-01182-7","volume":"40","author":"L Wang","year":"2022","unstructured":"Wang L, Cao J, Li C, Wang X, Zhao Y, Li T, et al. Efficacy and safety of mitoxantrone hydrochloride liposome injection in Chinese patients with advanced breast cancer: a randomized, open-label, active-controlled, single-center, phase II clinical trial. Invest New Drugs. 2022;40(2):330\u20139.","journal-title":"Invest New Drugs"},{"key":"4724_CR192","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.ejca.2022.03.004","volume":"168","author":"N Masuda","year":"2022","unstructured":"Masuda N, Ono M, Mukohara T, Yasojima H, Shimoi T, Kobayashi K, et al. Phase 1 study of the liposomal formulation of eribulin (E7389-LF): Results from the breast cancer expansion cohort. Eur J Cancer. 2022;168:108\u201318.","journal-title":"Eur J Cancer"},{"issue":"15","key":"4724_CR193","doi-asserted-by":"publisher","first-page":"4190","DOI":"10.1158\/1078-0432.CCR-16-3193","volume":"23","author":"H Lee","year":"2017","unstructured":"Lee H, Shields AF, Siegel BA, Miller KD, Krop I, Ma CX, et al. (64)Cu-MM-302 Positron Emission Tomography Quantifies Variability of Enhanced Permeability and Retention of Nanoparticles in Relation to Treatment Response in Patients with Metastatic Breast Cancer. Clin Cancer Res. 2017;23(15):4190\u2013202.","journal-title":"Clin Cancer Res"},{"issue":"9","key":"4724_CR194","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1038\/s41416-018-0235-2","volume":"119","author":"P Munster","year":"2018","unstructured":"Munster P, Krop IE, LoRusso P, Ma C, Siegel BA, Shields AF, et al. Safety and pharmacokinetics of MM-302, a HER2-targeted antibody-liposomal doxorubicin conjugate, in patients with advanced HER2-positive breast cancer: a phase 1 dose-escalation study. Br J Cancer. 2018;119(9):1086\u201393.","journal-title":"Br J Cancer"},{"issue":"2","key":"4724_CR195","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1007\/s10549-018-05070-2","volume":"174","author":"O Nanni","year":"2019","unstructured":"Nanni O, Amadori D, De Censi A, Rocca A, Freschi A, Bologna A, et al. Metformin plus chemotherapy versus chemotherapy alone in the first-line treatment of HER2-negative metastatic breast cancer. The MYME randomized, phase 2 clinical trial. Breast Cancer Res Treat. 2019;174(2):433\u201342.","journal-title":"Breast Cancer Res Treat"},{"issue":"3","key":"4724_CR196","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1007\/s10637-023-01357-4","volume":"41","author":"N Abuhadra","year":"2023","unstructured":"Abuhadra N, Sun R, Bassett RL Jr., Huo L, Chang JT, Teshome M, et al. Targeting chemotherapy resistance in mesenchymal triple-negative breast cancer: a phase II trial of neoadjuvant angiogenic and mTOR inhibition with chemotherapy. Invest New Drugs. 2023;41(3):391\u2013401.","journal-title":"Invest New Drugs"},{"key":"4724_CR197","doi-asserted-by":"publisher","first-page":"103725","DOI":"10.1016\/j.breast.2024.103725","volume":"75","author":"L Orlando","year":"2024","unstructured":"Orlando L, Maiello E, Orditura M, Diana A, Antoniol G, Morritti MG, et al. Phase II randomized trial comparing metronomic anthracycline-containing chemotherapy versus standard schedule in untreated HER2 negative advanced breast cancer: activity and quality of life results of the GOIM 21003 trial. Breast. 2024;75:103725.","journal-title":"Breast"},{"key":"4724_CR198","doi-asserted-by":"publisher","unstructured":"Wei Z, Zhuo S, Zhang Y, Wu L, Gao X, He S, et al. Machine learning reshapes the paradigm of nanomedicine research. Acta Pharmaceutica Sinica B. 2025 https:\/\/doi.org\/10.1016\/j.apsb.2025.05.014","DOI":"10.1016\/j.apsb.2025.05.014"},{"issue":"5","key":"4724_CR199","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/j.tibtech.2021.01.009","volume":"39","author":"AA Ashkarran","year":"2021","unstructured":"Ashkarran AA, Swann J, Hollis L, Mahmoudi M. The File Drawer Problem in Nanomedicine. Trends Biotechnol. 2021;39(5):425\u20137.","journal-title":"Trends Biotechnol"},{"key":"4724_CR200","first-page":"30573","volume":"15","author":"D Tripathi","year":"2025","unstructured":"Tripathi D, Pandey P, Sharma S, Rai AK, Prabhu BHM. Advances in nanomaterials for precision drug delivery: Insights into pharmacokinetics and toxicity. Bioimpacts. 2025;15:30573.","journal-title":"Bioimpacts"},{"key":"4724_CR201","doi-asserted-by":"publisher","first-page":"22","DOI":"10.3390\/ijms262211121","volume":"26","author":"Y Han","year":"2025","unstructured":"Han Y, Kim DH, Pack SP. Nanomaterials in Drug Delivery: Leveraging Artificial Intelligence and Big Data for Predictive Design. Int J Mol Sci. 2025;26:22.","journal-title":"Int J Mol Sci"},{"issue":"2","key":"4724_CR202","doi-asserted-by":"publisher","first-page":"lsaf028","DOI":"10.1093\/jlb\/lsaf028","volume":"12","author":"G Lenarczyk","year":"2025","unstructured":"Lenarczyk G, Minssen T, Price N, Rai A. The future of AI regulation in drug development: a comparative analysis. J Law Biosci. 2025;12(2):lsaf028.","journal-title":"J Law Biosci"},{"issue":"1","key":"4724_CR203","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1038\/s41698-024-00517-w","volume":"8","author":"B Derraz","year":"2024","unstructured":"Derraz B, Breda G, Kaempf C, Baenke F, Cotte F, Reiche K, et al. New regulatory thinking is needed for AI-based personalised drug and cell therapies in precision oncology. NPJ Precis Oncol. 2024;8(1):23.","journal-title":"NPJ Precis Oncol"},{"issue":"3","key":"4724_CR204","doi-asserted-by":"crossref","DOI":"10.1016\/S0025-6196(26)07960-7","volume":"3","author":"V Singh","year":"2025","unstructured":"Singh V, Cheng S, Kwan AC, Ebinger J. United States Food and Drug Administration regulation of clinical software in the era of artificial intelligence and machine learning. Mayo Clinic Proceedings: Digital Health. 2025;3(3):100231.","journal-title":"Mayo Clinic Proceedings: Digital Health"},{"issue":"10","key":"4724_CR205","doi-asserted-by":"publisher","first-page":"e30545","DOI":"10.2196\/30545","volume":"23","author":"S Gilbert","year":"2021","unstructured":"Gilbert S, Fenech M, Hirsch M, Upadhyay S, Biasiucci A, Starlinger J. Algorithm Change Protocols in the Regulation of Adaptive Machine Learning-Based Medical Devices. J Med Internet Res. 2021;23(10):e30545.","journal-title":"J Med Internet Res"},{"issue":"12","key":"4724_CR206","doi-asserted-by":"publisher","first-page":"2289","DOI":"10.1007\/s11095-024-03798-9","volume":"41","author":"V Agrahari","year":"2024","unstructured":"Agrahari V, Choonara YE, Mosharraf M, Patel SK, Zhang F. The Role of Artificial Intelligence and Machine Learning in Accelerating the Discovery and Development of Nanomedicine. Pharm Res. 2024;41(12):2289\u201397.","journal-title":"Pharm Res"},{"key":"4724_CR207","doi-asserted-by":"publisher","first-page":"1544393","DOI":"10.3389\/fmed.2025.1544393","volume":"12","author":"FD Rodr\u00edguez-G\u00f3mez","year":"2025","unstructured":"Rodr\u00edguez-G\u00f3mez FD, Monferrer D, Penon O, Rivera-Gil P. Regulatory pathways and guidelines for nanotechnology-enabled health products: a comparative review of EU and US frameworks. Front Med (Lausanne). 2025;12:1544393.","journal-title":"Front Med (Lausanne)"},{"key":"4724_CR208","doi-asserted-by":"publisher","first-page":"125625","DOI":"10.1016\/j.ijpharm.2025.125625","volume":"681","author":"CL Mustoe","year":"2025","unstructured":"Mustoe CL, Turner AJ, Urwin SJ, Houson I, Feilden H, Markl D, et al. Quality by digital design to accelerate sustainable medicines development. Int J Pharm. 2025;681:125625.","journal-title":"Int J Pharm"}],"container-title":["Journal of Nanobiotechnology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12951-026-04724-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12951-026-04724-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12951-026-04724-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T14:03:31Z","timestamp":1789394611000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12951-026-04724-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,28]]},"references-count":208,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4724"],"URL":"https:\/\/doi.org\/10.1186\/s12951-026-04724-4","relation":{},"ISSN":["1477-3155"],"issn-type":[{"value":"1477-3155","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,28]]},"assertion":[{"value":"10 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"866"}}